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Abstract
As a part of our project aimed at searching new safe chemotherapeutic agents against parasitic 
diseases, several compounds structurally related to the antiparasitic agent WC-9 (4-
phenoxyphenoxyethyl thiocyanate), which were modified at the terminal phenyl ring, were 
designed, synthesized and evaluated as growth inhibitors against Trypanosoma cruzi, the 
etiological agent of Chagas disease and Toxoplasma gondii, the parasite responsible of 
toxoplasmosis. Most of the synthetic analogues exhibited similar antiparasitic activity being 
slightly more potent than our lead WC-9. For example, the trifluoromethyl derivatives 15 and 16 
exhibited ED50 values of 10.0 μM and 9.2 μM, respectively, against intracellular T. cruzi, whereas 
they showed potent action against tachyzoites of T. gondii (ED50 values 1.6 μM and 1.9 μM 
against T. gondii, respectively). In addition, the WC-9 analogues 48 and 61, in which the terminal 
aryl group was meta with respect to the alkyl chain bearing the thiocyanate group, showed potent 
inhibitory action against both T. cruzi and T. gondii at the very low micromolar range suggesting 
that para-phenyl substitution pattern is not necessarily required for biological activity.
Graphical Abstract
WC-9 is a well-known antichagasic agent targeting squalene synthase. We describe the design, 
synthesis, and biological evaluation of WC-9 analogues bearing either the aryloxy moiety bonded 
at the C-4′ position of the A ring or at the C-3′ one. Some of them turn out to be effective growth 
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inhibitors of both Trypanosoma cruzi and Toxoplasma gondii, the etiologic agent of Chagas 
disease and toxoplasmosis, respectively.
Introduction
Trypanosomatids have a strict requirement for specific endogenous sterols for survival and 
cannot use the abundant supply of cholesterol present in their mammalian hosts.[1–5] For that 
reason, ergosterol biosynthesis has become a valid target to control parasitic diseases caused 
by pathogenic trypanosomatids. It has been reported that ergosterol biosynthesis inhibitors 
with potent in vitro activity and special pharmacokinetic properties in mammals can induce 
radical parasitological cure in animal models of both acute and chronic experimental Chagas 
disease.[6,7] 4-Phenoxyphenoxyethyl thiocyanate (compound 1; WC-9) is an interesting 
drug that presents ED50 values at the low nanomolar range against the clinically more 
relevant replicative form (amastigotes) of Trypanosoma cruzi,[8–10] the etiological agent of 
Chagas disease or American trypanosomiasis (Figure 1). WC-9 induces a dose dependent 
effect of growth of the epimastigotes (EP strain).[11] In addition, the growth inhibitory 
effects of WC-9 are associated with a depletion of the parasite endogenous sterols, 
ergosterol and its 24-ethyl analogue with no accumulation of sterol intermediates or 
precursors indicating a blockade of the biosynthetic pathway at a pre-squalene level.[11]
Squalene synthase (SQS) is a crucial enzyme in isoprenoid biosynthesis, which catalyzes the 
first committed step in ergosterol biosynthesis, where a reductive dimerization of two 
molecules of farnesyl pyrophosphate takes place to form squalene. It has been determined 
that the precise mode of action of WC-9 is an inhibitor of the enzymatic activity of T cruzi 
SQS,[11] employing as enzyme source highly purified glycosomes and mitochondrial 
membrane vesicles obtained from T. cruzi epimastigotes.[12] WC-9 is a potent inhibitor of 
both glycosomal and mitochondrial T.cruzi SQS, with IC50 values of 88 nM and 129 nM. 
The dose-response curves for the activity of WC-9 against TcSQS were consistent with non-
competitive inhibition with Ki = IC50; these Ki values are two to three orders of magnitude 
lower that the Km of the substrates.[11]
Apicompexan parasite such as Toxoplasma gondii, the responsible agent of toxoplasmosis, 
lacks the mevalonate pathway and uses a prokaryotic-type 1-deoxy-D-xylulose-5-phosphate 
(DOXP) pathway instead to make IPP and DMAPP. The DOXP pathway localizes to the 
apicoplast and is essential.[13] It has been demonstrated that T. gondii does not synthesize 
cholesterol and imports it from the host[14] suggesting that inhibitors of the host SQS could 
potentially inhibit T. gondii growth. The fact that WC-9 and closely related analogues were 
growth inhibitor of T. gondii is quite in agreement with other authors work that has shown 
that mevalonate pathway inhibitors are active against Apicomplexan parasites such as 
Babesia divergens,[15] Plasmodium falciparum,[15,16] Cryptosporidium parvum,[17] and T. 
gondii,[18] indicating that these parasites, which lack the mevalonate pathway, are dependent 
on host biosynthesis of precursors of the isoprenoid pathway. In this regard, it has recently 
been demonstrated that T. gondii acquires isoprenoid intermediates like farnesyl diphosphate 
and/or geranylgeranyl diphosphate from the host cell produced by the mevalonate 
pathway.[19]
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Rationale
To date the crystal structure of TcSQS with WC-9 is not available. However, the X-ray 
crystallographic structure of WC-9 bound to dehydrosqualene synthase (CrtM) from 
Staphylococcus aureus has been recently published.[20] This enzyme catalyzes 
dehydrosqualene formation, a metabolite that is further transformed into staphyloxanthin. It 
has been postulated that WC-9 might bind into the same hydrophobic S2 pocket in TcSQS 
as it does in dehydrosqualene synthase keeping the same polar interactions with the 
thiocyanate group.[20] Besides, lately it was possible to obtain crystals of WC-9 bound to 
human SQS but all the attempts to do so with TcSQS were unsuccessful.[21]
Based on WC-9 chemical structure, we have conducted a meticulous structure activity / 
biological activity relationship studies that lead to the assumption that the phenoxyethyl 
thiocyanate moiety (colored in red in Figure 1) should be considered as the structure of the 
pharmacophore.[8–10,22–24] Although WC-9 is able to impair parasitemia in murine models 
of Chagas disease the level of protection is not as efficient as ketoconazole, used as a 
positive control.[25] This lack of in vivo efficacy of WC-9 may be attributed to poor 
pharmacokinetic properties, which indeed should be improved. In this respect, the finding 
that structural variations at the B ring of WC-9 had a marked influence on biological activity 
encouraged us to follow this approach. As a matter of fact, the introduction of a fluorine 
atom at the B ring of WC-9 gives rise to compounds 2 and 3, which have estimated log P 
values of 4.71 versus log P of 4.51 for WC-9, indicating a better distribution between water/
octanol. In fact, both of these compounds, 2 and 3, are significantly more potent than WC-9 
in in vitro assays (Figure 1).[23]
The question that arises is how is it possible to optimize the chemical structure of WC-9 
without knowing the binding site at the target enzyme? The availability of this information 
would be very important in order to design rationally more effective non-competitive 
inhibitors structurally related to WC-9.
The Buchwald coupling reaction has proven to be a reliable method to prepare asymmetric 
substituted diaryl ethers or even diaryl amines.[26] Certainly, a variety of WC-9 analogues 
bearing different substituents either at the A ring or B ring has been prepared employing this 
protocol,[24] which is a reliable alternate method to get these type of compounds avoiding 
the use of expensive and not always commercially available phenylboronic acids as starting 
materials.[27]
Results and Discussion
Therefore, following a classical approach, the structural variations considered were those 
that involved different substitutions at the B ring as well as the relative position of the B ring 
to the aliphatic chain. The introduction of an electron withdrawing moiety at the B ring such 
as the trifluoromethyl group was the first structural modification considered. Then, 
employing commercially available 4-(benzyloxy)phenol (6), this compound was converted 
into the tetrahydropyranyl ether derivative 7 in 96% yield by treatment with 2-bromoethyl 
tetrahydro-2H-pyran-2-yl ether in a suspension of potassium hydroxide in dimethyl 
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sulfoxide, following to a slightly modified Williamson reaction.[28] Removal of the 
protecting benzyl group was carried out by treatment with hydrogen at 3 atm and room 
temperature, in the presence of palladium on charcoal, to afford phenol 8 in 73% yield, 
which on treatment with 1-iodo-3-(trifluoromethyl)benzene in the presence of 5% cuprous 
iodide, 10% picolinic acid and potassium phosphate according to the Buchwald protocol 
produced the conveniently functionalized diaryl ether 9 in 86% yield. Buchwald coupling 
reaction between 8 and 1-iodo-4-(trifluoromethyl)benzene gave 10 in 32% yield. Compound 
9 was deprotected by treatment with pyridinium p-toluenesulfonate in methanol to afford the 
corresponding free alcohol 11 in 62% yield, which, in turned, was treated with tosyl chloride 
in pyridine to give tosylate 13 in 86% yield. 13 was further transformed into the thiocyanate 
derivative 15 by treatment with potassium thiocyanate in N,N-dimethylformamide at 100 °C 
in 36% yield (Scheme 2). In a similar strategy, 10 was transformed into alcohol 12, which 
was reacted with tosyl chloride to give 14, which was finally transformed into the title 
compound 16 by treatment with potassium thiocyanate as illustrated in Scheme 2.
In order to study the influence of the polarity of the terminal phenyl group, it was conceived 
the replacement of this ring by a naphtyl group giving rise to title compounds 20 and 24, 
whose estimated log P values were both 5.2 versus 4.2 corresponding to the WC-9 
molecule. Buchwald coupling reaction of 8 either with 2-bromonaphtalene or 1-
bromonaphtalene afforded the diaryl ether derivatives 17 and 21 in low but reproducible 
yields of 18% and 32%, respectively. Following the general strategy each tetrahydropyranyl 
protecting group present in 17 and 21 was cleaved by treatment with pyridinium p-
toluenesulfonate affording the corresponding free alcohols 18 and 22 in good yields, which 
were tosylated to give 19 and 23. On treatment with potassium thiocyanate, in separate 
experiments, these compounds were converted into the target molecules 20 and 24, 
respectively, as illustrated in Scheme 2.
We have recently described a pyridyl analogue of WC-9 where the nitrogen atom occupied 
the 3″ position.[24] In order to complete the structure / activity analysis it was decided to 
prepare the corresponding pyridyl derivative where the nitrogen atom was placed at the C-2″ 
position giving rise to the target molecule 29. The incorporation of the pyridyl unit was 
carried out through a Buchwald coupling reaction between the already depicted 4-
iodophenoxyethyl tetrahydro-2H-pyran-2-yl ether (25) with 2-hydrozypyridine to produce 
tetrahydro pyranyl derivative 26 in 48% yield. Once this adduct was at hand, and similarly 
to the preparation of 16 and 17, cleavage of tetrahydropyranyl protecting group of 26 to give 
free alcohol 27, followed by tosylation to produce 28, and further substitution of the tosylate 
group by the thiocyanate ion afforded the title compound 29 in reaction yields of 60%, 90%, 
and 61%, respectively (Scheme 3).
At the present time it is not conclusive which one is the optimal relative position of terminal 
phenyl of WC-9. We have recently demonstrated that analogues where the phenyl group 
was at the C-3′ position exhibited antiparasitic activity almost of the same efficacy as those 
compounds bearing this group at the C-4′ position.[24] Therefore, it was conceived several 
regioisomers of WC-9 bearing different either chlorine or a methoxy group at diverse 
positions of the terminal ring such as 46–50. The synthetic strategy to obtain these 
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compounds is presented in Scheme 4 employing the already described 3-iodophenoxyethyl 
tetrahydro-2H-pyran-2-yl ether (30) as a common starting material.[24] This compound was 
reacted with five substituted phenols like 2-chloro, 3-chloro, 4-chloro, 2-methoxy, and 3-
methoxyphenol under the usual Buchwald coupling procedures giving rise to the expected 
asymmetric diaryl ethers 31–35 in a range from moderate to good yields. Then, following 
the general method in individual experiments, each of these compounds suffered from 
tetrahydropyranyl cleavage to give 36–40, further tosylation to form tosylates 41–45 and 
nucleophilic displacement of the tosylate group by treatment with potassium thiocyante to 
afford the expected regioisomers of WC-9, that is, compounds 46–50, respectively (Scheme 
4).
Pyridyl regioisomers analogues of WC-9 such as 60–62 were other interesting structural 
variations considered yielding polar compounds (estimated log P = 2.82) and keeping the 
pharmacophore into the molecules. In this case, the synthesis of the title compounds was not 
straightforward, particularly, for the preparation of 62 as will be discussed later. Then, 
compound 30 was used as a committed starting material, which, on separate experiments, 
was reacted with 2-hydroxy-, 3-hydroxy-, and 4-hydroxypyridine under Buchwald coupling 
reaction conditions to give rise to coupled products 51–53 in moderate yields, which were 
easily deprotected by treatment with pyridinium p-toluenesulfonate to yield the 
corresponding free alcohols 54–56. On treatment with excess of tosyl chloride 54 and 55 
were converted into tosylates 57 and 58, respectively; while the corresponding tosylate of 
alcohol 56 could not be obtain due to formation of a tosylpyridinium ion, which not only 
consumes reagent, but also forms an extremelly polar species that hinders the reaction.[29] 
This problem was circumvented by the preparation of the bromide derivative 59. Then, on 
treatment with N-bromosuccinimide and triphenylphosphine 56 was converted into 69.[30] 
The title compounds 60–62 were obtained by treatment of tosylates 57 and 58, or bromine 
59 with potassium thiocyate in good yields (Scheme 5).
The thiocyanate group in WC-9 and other closely related analogues seems to be essential for 
biological activity. In order to study the influence of this group on biological action it was 
considered to replace it by other electrophilic group such as the azido moiety. Thus, the 
already described tosylate 63, treated with sodium azide in N,N-dimethylformamide 
afforded the title compound 64 (Scheme 6).
Previous biological data had indicated that a simplified analogue of WC-9 (2,4-
dichlorophenoxyethyl thiocyanate), in which the aromatic skeleton was a 2,4-dichlorophenyl 
group instead of a 4-phenoxyphenyl moiety, exhibited similar anti Chagasic activity as our 
lead compound WC-9.[9] Then, it would seem of interest to evaluate the corresponding 
bromine analogue 68. Thus, synthesis of Williamson between 2,4-dibromophenol and bromo 
ethyl tetrahydropyranyl ether afforded 65, which after hydrolysis of the tetrahydropyranyl 
group followed by treatment with tosyl chloride and further nucleophilic attack of potassium 
thiocyanate led the title compound 68 (Scheme 7).
Finally, as a part of the strategy to evaluate very simple structure, the pyridyl derivative 72 
was considered as a polar and very simple structure having an estimated log P value of 1.32. 
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This compound was prepared straightforwardly from 3-hydroxypyridine following the 
general method as described in Scheme 8.
Biological evaluation of these new WC-9 analogues was very encouraging. The title 
compounds 15 and 16 were potent growth inhibitors of the intracellular form of T. cruzi, 
which is the clinically more relevant replicative form of the parasite. Certainly, both of these 
compounds bearing an electron withdrawing group at the C-3″ and the C-4″ positions 
exhibited ED50 values quite similar compared to WC-9, used as a positive control, under the 
same assay conditions. Compounds 15 and 16 were also potent inhibitors of T. gondii 
(tachyzoites) growth possessing ED50 values at the very low micromolar level (1.6 μM and 
2.0 μM, respectively). The introduction of a naphtyl group as a terminal B ring of WC-9 was 
not beneficial for the anti-T. cruzi activity giving rise to 20 and 24, which are devoid of 
action against amastigotes of T. cruzi. Interestingly, 20 and 24 exhibited potent inhibitory 
action against tachyzoites of T. gondii with ED50 values of 2.3 μM and 2.9 μM, respectively. 
Surprisingly, in spite of having the pharmacopore moeity in the structure, pyridyl derivative 
29 was devoid of antiparasitic activity against both T. cruzi and T. gondii. With the 
exception of 47, which presented vanishing biological activity, the regioisomers of WC-9 
bearing electron-donor groups at the terminal ring 46–50 showed potent inhibitory action 
against T. cruzi and T. gondii being 48 and 50 those with similar efficacy compared with 
WC-9. Interestingly, all of them were very potent growth inhibitors of tachyzoites of T. 
gondii showing ED50 values of 2.1 μM, 3.9 μM, 2.8 μM and 4.0 μM, respectively, as shown 
in Table 1. Only the pyridyl analogues of the regioisomer of WC-9 61 showed potent 
antiparasitic action having ED50 values of 7.5 μM and 3.7 μM against T. cruzi and T. gondii, 
respectively. The rest of these pyridyl derivatives, that is, 60 and 62, are free of antiparasitic 
activity. Evidently, the relative position of the nitrogen atom at the B ring plays a key role in 
modulating the biological activity. Unexpectedly, the dibromo derivative 68 was inactive as 
an antiparasitic agent based on the results previously exhibited by the parent dichloro 
analogue.[9] Finally, the simple pyridyl derivative 72 was devoid of antiparasitic activity as 
well. These data were in agreement with our previous results[24] confirming that the para-
aryl substitution pattern of WC-9 would not be necessarily required for an effective 
biological activity. The results are presented in Table 1.
Conclusions
It can be concluded that, most of the title compounds behave as anti-T. cruzi agents as well 
as anti-Toxoplasma agents favoring the latter ones. The key reaction to access these 
compounds was the Buchwald coupling reaction, which has proven to be reliable not only to 
obtain WC-9 derivatives modified at the B ring, but also to synthesize substituted 
derivatives at the A ring in the future. The promising biological activity observed of the 
target molecules together with the drug-like character of these compounds motivate new 
studies to find an optimized chemical structure knowing the precise mode of action. Efforts 
in these aspects are currently being pursued in our laboratory.
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Experimental Section
The glassware used in air and/or moisture sensitive reactions was flame-dried and carried 
out under a dry argon atmosphere. Unless otherwise noted, chemicals were commercially 
available and were used without further purification. Anhydrous N,N-dimethylformamide 
and anhydrous dimethyl sulfoxide were used as supplied from Aldrich.
Nuclear magnetic resonance spectra were obtained using a Bruker AM-500 MHz 
spectrometer. Chemical shifts are reported in parts per million (δ) relative to 
tetramethylsilane. Coupling constants are reported in Hertz. 13C NMR spectra were fully 
decoupled. Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet.
High-resolution mass spectra were performed using a Bruker micrOTOF-Q II spectrometer, 
which is a hybrid quadrupole time of flight mass spectrometer with MS/MS capability.
Melting points were determined using a Fisher-Johns apparatus and are uncorrected.
Column chromatography was performed with E. Merck silica gel plates (Kieselgel 60, 230–
400 mesh). Analytical thin layer chromatography was performed employing 0.2 mm coated 
commercial silica gel plates (E. Merck, DC-Aluminum sheets, Kieselgel 60 F254).
4-Benzyloxyphenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (7)
A solution of 4-(benzyloxy)phenol (6; 5.00 g, 25.0 mmol) in dimethyl sulfoxide (25 mL) 
was treated with potassium hydroxide (2.81 g, 50.0 mmol). The mixture was stirred at room 
temperature for 5 min. Then, bromoethyl tetrahydropyranyl ether (6.27 g, 30.0 mmol) was 
added, and the reaction mixture was stirred at room temperature overnight. The mixture was 
partitioned between water (70 mL) and methylene chloride (70 mL). The aqueous phase was 
extracted with methylene chloride (2 × 40 mL). The combined organic layers were washed 
with a saturated solution of sodium chloride (5 × 50 mL), dried (MgSO4), and the solvent 
was evaporated. The product was purified by column chromatography eluting with hexane–
EtOAc (19:1) to yield 7.89 g (96% yield) of pure compound 7 as a colorless oil: Rf 0.63 
(hexane–EtOAc, 7:3); 1H NMR (200 MHz, CDCl3) δ 1.46–1.88 (m, 6H, H-3‴, H-4‴, 
H-5‴), 3.45–3.61 (m, 1H, H-6‴a), 3.70–4.05 (m, 3H, H-1, H-6‴b), 4.05–4.18 (m, 2H, H-2), 
4.72 (dist. t, J = 3.2 Hz, 1H, H-2‴), 5.02 (s, 2H, PhCH2O-), 6.87 (d, J = 9.3 Hz, 2H, H-3′), 
6.92 (d, J = 9.3 Hz, 2H, H-2′), 7.24–7.47 (m, 5H, aromatic protons); 13C NMR (125.77 
MHz, CDCl3) δ 19.4 (C-4‴), 25.4 (C-5‴), 30.5 (C-3‴), 62.2 (C-6‴), 65.9 (C-1), 68.1 (C-2), 
70.7 (PhCH2O-), 99.0 (C-2‴), 115.7 (C-3′), 115.8 (C-2′, C-3′), 127.5 (C-2″), 127.9 (C-4″), 
128.5 (C-3″), 137.3 (C-1″), 153.1 (C-1′), 153.3 (C-4′). HRMS (ESI) calcd. for C20H24O4Na 
[M+Na]+ 351.1572; found 351.1574.
4-Hydroxyphenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (8)
A solution of 7 (8.150 g, 24.8 mmol) in ethyl acetate (40 mL) in the presence of 5% 
palladium on charcoal (40 mg) was treated with hydrogen at 3 atm. The reaction was stirred 
at room temperature for 4 h. The mixture was filtered off and the solvent was evaporated. 
The residue was purified by column chromatography (silica gel) employing hexane–EtOAc 
(4:1) as eluant to produce 4.301 g (73% yield) of pure 8 as a colorless oil: Rf 0.27 (hexane–
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EtOAc; 7:3); 1H NMR (500.13 MHz, CDCl3) δ 1.51–1.68 (m, 4H, H-4″, H-5″), 1.72–1.77 
(m, 1H, H-3″a), 1.81–1.88 (m, 1H, H-3″b), 3.51–3.56 (m, 1H, H-6″a), 3.79 (ddd, J = 11.1, 
6.4, 4.1 Hz, 1H, H-6‴b), 3.92 (m, 1H, H-1a), 4.03 (m, 1H, H-1b), 4.11 (m, 2H, H-2), 4.71 (t, 
J = 3.7 Hz, 1H, H-2″), 6.75 (d, J = 9.1 Hz, 2H, H-3′), 6.81 (d, J = 8.9 Hz, 2H, H-2′); 13C 
NMR (125.77 MHz, CDCl3) δ 19.3 (C-4″), 25.4 (C-5″), 30.5 (C-3″), 62.2 (C-6″), 66.0 
(C-1), 68.1 (C-2), 99.0 (C-2″), 115.9 (C-2′), 116.0 (C-3′), 149.7 (C-4′), 153.0 (C-1′). HRMS 
(ESI) calcd. for C13H18O4Na [M+Na]+ 261.1103; found 261.1088.
4-[(3-Trifluoro)phenoxy]phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (9)
A mixture of compound 8 (1.50 g, 6.29 mmol), 1-iodo-3-(trifluoromethyl)benzene (2.06 g, 
7.56 mmol), copper(I) iodide (120 mg, 0.63 mmol), 2-picolinic acid, (155 mg, 1.26 mmol), 
and potassium phosphate tribasic (2.68 g, 12.6 mmol) under anhydrous conditions was 
evacuated and backfilled with argon. This sequence was repeated twice. Then, dimethyl 
sulfoxide was added (15.0 mL) and the reaction mixture was stirred vigorously at 80 °C for 
36 h. The mixture was cooled to room temperature and partitioned between ethyl acetate (20 
mL) and water (20 mL). The aqueous layer was extracted with ethyl acetate (2 × 20 mL). 
The combined organic phases were washed with brine (5 × 50 mL), dried (MgSO4), and the 
solvent was evaporated. The product was purified by column chromatography (silica gel) 
employing hexane–EtOAc (19:1) as eluent to afford 2.06 g (86% yield) of pure 9 as a 
colorless oil: Rf 0.64 (hexane–EtOAc; 7:3); 1H NMR (500.13 MHz, CDCl3) δ 1.53–1.68 (m, 
4H, H-4‴, H-5‴), 1.72–1.78 (m, 1H, H-3‴a), 1.81–1.87 (m, 1H, H-3‴b), 3.53 (m, 1H, 
H-6‴a), 3.82 (ddd, J = 11.2, 6.3, 4.2 Hz, 1H, H-6‴b), 3.91 (ddd, J = 11.3, 8.2, 3.1 Hz, 1H, 
H-1a), 4.07 (ddd, J = 11.1, 4.9, 4.3 Hz, 1H, H-1b), 4.16 (m, 2H, H-2), 4.72 (t, J = 3.6 Hz, 
1H, H-2‴), 6.94 (d, J = 9.3 Hz, 2H, H-2′), 7.98 (d, J = 9.3 Hz, 2H, H-3′), 7.09 (dd, J = 8.2, 
2.1 Hz, 1H, H-6″), 7.16 (t, J = 1.9 Hz, 1H, H-2″), 7.28 (dt, J = 7.8, 0.7 Hz, 2H, H-4″), 7.39 
(t, J = 8.0 Hz, 2H, H-5″); 13C NMR (125.77 MHz, CDCl3) δ 19.4 (C-4‴), 25.4 (C-5‴), 30.5 
(C-3‴), 62.2 (C-6‴), 65.9 (C-1), 67.9 (C-2), 99.0 (C-2‴), 114.0 (q, J = 3.9 Hz, C-2″), 116.0 
(C-2′), 118.9 (q, J = 3.8 Hz, C-4″), 120.4 (C-5″), 130.1 (C-6″), 149.1 (C-4′), 155.8 (C-1′), 
160.0 (C-1″); 19F NMR (470.54 MHz, CDCl3) δ −62.71. HRMS (ESI) calcd. for 
C20H21O4F3Na [M+Na]+ 405.129; found 405.1285.
4-[(4-Trifluoro)phenoxy]phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (10)
A mixture of compound 8 (433 mg, 1.82 mmol), 1-iodo-4-(trifluoromethyl)benzene (594 
mg, 2.18 mmol), copper(I) iodide (34.6 mg, 0.36 mmol), 2-picolinic acid, (44.8 mg, 0.36 
mmol), and potassium phosphate tribasic (773 g, 3.64 mmol) in dimethyl sulfoxide (6.0 mL) 
was treated as described for the preparation of 9 for 13 days. The residue was purified by 
column chromatography (silica gel) employing hexane–EtOAc (19:1) as eluent to give 225 g 
(32% yield) of pure 10 as a colorless oil: Rf 0.60 (hexane–EtOAc, 7:3); 1H NMR (500.13 
MHz, CDCl3) δ 1.53–1.67 (m, 4H, H-4‴, H-5‴), 1.73–1.79 (m, 1H, H-3‴a), 1.82–1.88 (m, 
1H, H-3‴b), 3.54 (m, 1H, H-6‴a), 3.82 (ddd, J = 11.2, 6.4, 4.4 Hz, 1H, H-6‴b), 3.91 (ddd, J 
= 11.3, 8.2, 3.1 Hz, 1H, H-1a), 4.07 (m, 1H, H-1b), 4.16 (m, 2H, H-2), 4.72 (t, J = 3.6 Hz, 
1H, H-2‴), 6.95 (d, J = 9.3 Hz, 2H, H-2′), 6.97 (m, 2H, H-2″), 6.99 (d, J = 9.3 Hz, 2H, 
H-3′), 7.56 (d, J = 8.9 Hz, 2H, H-3″); 13C NMR (125.77 MHz, CDCl3) δ 19.4 (C-4‴), 25.4 
(C-5‴), 30.5 (C-3‴), 62.2 (C-6‴), 65.8 (C-1), 67.9 (C-2), 99.0 (C-2‴), 116.0 (C-2′), 116.8 
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(C-3′), 121.5 (C-2″), 127.0 (q, J = 3.8 Hz, C-3″), 148.8 (C-4′), 156.0 (C-1′), 161.5 
(C-1″); 19F NMR (470.59 MHz, CDCl3) δ −61.66. HRMS (ESI) calc. for C20H21F3NaO4 
[M+Na]+ 405.1290; found 405.1286.
4-[(3-Trifluoro)phenoxy]phenoxyethanol (11)
A solution of compound 9 (1.96 g, 5.13 mmol) in methanol (50 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg). The reaction mixture was stirred at room 
temperature overnight. Then, water (70 mL) was added, and the mixture was extracted with 
methylene chloride (3 × 50 mL). The combined organic layers were washed with brine (3 × 
50 mL), dried (MgSO4), and the solvent was evaporated. The residue was purified by 
column chromatography (silica gel) eluting with hexane–EtOAc (17:1) to give 944.0 mg 
(62% yield) of pure alcohol 11 as a colorless oil: Rf 0.30 (hexane–EtOAc, 7:3); 1H NMR 
(500.13 MHz, CDCl3) δ 2.03 (t, J = 5.5 Hz, 1H, -OH), 3.99 (m, 2H, H-1), 4.01 (t, J = 4.5 
Hz, 2H, H-2), 6.94 (d, J = 9.1 Hz, 2H, H-2′), 7.00 (d, J = 9.1 Hz, 2H, H-3′), 7.10 (dd, J = 
8.3, 2.4 Hz, 1H, H-6″), 7.17 (t, J = 1.9 Hz, 1H, H-2″), 7.29 (d, J = 7.7 Hz, 2H, H-4″), 7.40 (t, 
J = 8.0 Hz, 2H, H-5″); 13C NMR (125.77 MHz, CDCl3) δ 61.5 (C-1), 69.7 (C-2), 114.1 (q, J 
= 3.9 Hz, C-2″), 115.9 (C-2′), 119.0 (q, J = 3.8 Hz, C-4″), 120.5 (C-5″), 130.2 (C-6″), 149.5 
(C-4′), 155.5 (C-1′), 158.8 (C-1″). HRMS (ESI) calcd. for C15H13O3F3Na [M + Na]+ 
321.0714; found 321.0703.
4-[(4-Trifluoro)phenoxy]phenoxyethanol (12)
A solution of compound 10 (229 mg, 0.60 mmol) in methanol (10 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg) as described for the preparation of 11. Purification 
by column chromatography (silica gel) eluting with hexane–EtOAc (17:1) afforded 174 mg 
(97% yield) of pure alcohol 12 as a white solid: Rf 0.20 (hexane–EtOAc, 7:3); 1H NMR 
(500.13 MHz, CDCl3) δ 3.99 (m, 2H, H-1), 4.10 (t, J = 4.5 Hz, 2H, H-2), 6.94 (d, J = 9.1 
Hz, 2H, H-2′), 6.98 (d, J = 8.5 Hz, 2H, H-2″), 7.01 (d, J = 9.1 Hz, 2H, H-3′), 7.54 (d, J = 8.6 
Hz, 2H, H-3″); 13C NMR (125.77 MHz, CDCl3) δ 61.5 (C-1), 69.7 (C-2), 115.8 (C-2′), 
116.9 (C-3′), 121.6 (C-2″), 127.0 (q, J = 3.7 Hz, C-3″), 149.1 (C-4′), 155.7 (C-1′), 161.4 
(C-1″); 19F NMR (470.54 MHz, CDCl3) δ −61.68. HRMS (ESI) calc. for C15H13F3NaO3 
[M+Na]+ 321.0714; found 321.0719.
4-[(3-Trifluoro)phenoxy]phenoxyethyl 4-Toluenesulfonate (13)
To a solution of alcohol 11 (922 mg, 3.09 mmol) in pyridine (5.0 mL) was added with p-
toluenesulfonyl chloride (1.72 g, 9.02 mmol) at 0 °C. The mixture was stirred at room 
temperature for 4 h. Then, 5% HCl (50 mL) was added and the reaction mixture was stirred 
for an additional hour. The mixture was extracted with methylene chloride (50 mL) and the 
organic layer was washed with 5% HCl (3 × 50 mL) and H2O (3 × 50 mL). The organic 
phase was dried (MgSO4) and the solvent was evaporated. The product was purified by 
column chromatography (silica gel) employing a mixture of hexane-EtOAc (19:1) as eluent 
to afford 1.29 g of tosylate 13 (86% yield) as a colorless oil. Rf 0.50 (hexane–EtOAc, 
7:3); 1H NMR (500.13 MHz, CDCl3) δ 2.45 (s, 3H, PhCH3), 4.16 (m, 2H, H-1), 4.38 (m, 
2H, H-2), 6.81 (d, J = 9.1 Hz, 2H, H-2′), 6.96 (d, J = 9.1 Hz, 2H, H-3′), 7.08 (dd, J = 8.2, 2.3 
Hz, 1H, H-6″), 7.15 (t, J = 1.9 Hz, 1H, H-2″), 7.29 (d, J = 7.7 Hz, 2H, H-4″), 7.35 (d, J = 8.0 
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Hz, 2H, H-3‴), 7.40 (t, J = 8.0 Hz, 2H, H-5″), 7.83 (d, J = 8.3 Hz, 2H, H-2‴); 13C NMR 
(125.77 MHz, CDCl3) δ 21.6 (CH3), 66.0 (C-1), 68.0 (C-2), 114.2 (q, J = 3.9 Hz, C-2″), 
116.0 (C-2′), 119.1 (q, J = 3.9 Hz, C-4″), 120.6 (C-6″), 121.1 (C-3′), 128.0 (C-2‴), 129.9 
(C-3‴), 130.2 (C-5″), 132.1 (q, J = 32.6 Hz, C-3″), 132.9 (C-4‴), 145.0 (C-1‴), 149.7 
(C-4′), 154.8 (C-1′), 158.7 (C-1″); 19F NMR (470.59 MHz, CDCl3) δ −62.71 (s). HRMS 
(ESI) calc for C22H19F3NaO5S [M+Na]+ 475.0803; found 475.0775.
4-[(4-Trifluoro)phenoxy]phenoxyethyl 4-Toluenesulfonate (14)
To a solution of alcohol 12 (176 mg, 0.59 mmol) in pyridine (3.0 mL) was added with p-
toluenesulfonyl chloride (352 mg, 1.84 mmol) at 0 °C. The reaction mixture was treated as 
depicted for the preparation of 13 to afford 249 mg (93% yield) of pure tosylate 14 as a 
colorless oil: Rf 0.50 (hexane-EtOAc, 7:3); 1H NMR (500.13 MHz, CDCl3) δ 2.45 (s, 3H, 
PhCH3), 4.16 (m, 2H, H-1), 4.38 (m, 2H, H-2), 6.81 (d, J = 9.1 Hz, 2H, H-2′), 6.966 (d, J = 
8.5 Hz, 2H, H-2″), 6.970 (d, J = 9.1 Hz, 2H, H-3′), 7.36 (d, J = 8.0 Hz, 2H, H-3‴), 7.54 (d, J 
= 8.6 Hz, 2H, H-3″), 7.83 (d, J = 8.3 Hz, 2H, H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.7 
(PhCH3) 66.0 (C-1), 68.0 (C-2), 116.0 (C-2′), 116.9 (C-3′), 121.5 (C-2″), 127.0 (q, J = 3.8 
Hz, C-3″), 128.0 (C-2‴), 129.9 (C-3‴), 132.9 (C-4‴), 145.0 (C-1‴), 149.4 (C-4′), 155.0 
(C-1′), 161.3 (C-1″); 19F NMR (470.54 MHz, CDCl3) δ −61.69. HRMS (ESI) calc. for 
C22H19O5F3SNa [M+Na]+ 475.0803; found 475.0809.
4-[(3-Trifluoro)phenoxy]phenoxyethyl Thiocyanate (15)
A solution of tosylate 13 (1.290 g, 2.85 mmol) in anhydrous N,N-dimethylformamide (10 
mL) was treated with potassium thiocyanate (1.390 g, 14.3 mmol). The reaction mixture was 
heated at 100 °C for 48 h. The mixture was allowed to cool to room temperature and water 
(20 mL) was added. The aqueous phase was extracted with methylene chloride (2 × 30 mL) 
and the combined organic layers were washed with brine (5 × 30 mL) and water (2 × 30 
mL). The solvent was dried (MgSO4) and evaporated. The residue was purified by column 
chromatography (silica gel) eluting with hexane–EtOAc (19:1) to give 346 mg (36% yield) 
of pure compound 15 as a colorless oil; Rf 0.51 (hexane–EtOAc, 7:3); 1H NMR (500.13 
MHz, CDCl3) δ 3.35 (t, J = 5.8 Hz, 2H, H-1), 4.33 (t, J = 5.8 Hz, 2H, H-2), 6.95 (d, J = 9.1 
Hz, 2H, H-2′), 7.01 (d, J = 9.1 Hz, 2H, H-3′), 7.11 (dd, J = 8.2, 2.3 Hz, 1H, H-6″), 7.18 (t, J 
= 2.0 Hz, 1H, H-2″), 7.30 (d, J = 7.7 Hz, 2H, H-4″), 7.41 (t, J = 8.0 Hz, 2H, H-5″); 13C 
NMR (125.77 MHz, CDCl3) δ 33.2 (C-1), 66.4 (C-2), 111.6 (SCN), 114.3 (q, J = 3.9 Hz, 
C-2″), 116.1 (C-2′), 119.2 (q, J = 3.8 Hz, C-4″), 120.6 (C-5″), 123.7 (q, J = 272.4 Hz, CF3), 
130.2 (C-6″), 132.1 (q, J = 32.6 Hz, C-3″), 150.1 (C-4′), 154.6 (C-1′), 158.6 (C-1″); 19F 
NMR (470.54 MHz, CDCl3) δ −62.70. HRMS (ESI) calcd for C16H12O2NSF3Na [M + Na]+ 
362.0439; found 362.0428.
4-[(4-Trifluoro)phenoxy]phenoxyethyl Thiocyanate (16)
A solution of tosylate 14 (249 mg, 0.55 mmol) in anhydrous N,N-dimethylformamide (4 
mL) was treated with potassium thiocyanate (266 mg, 2.73 mmol). The reaction mixture was 
heated at 100 °C for 48 h. The reaction was work-up as depicted for the preparation of 15. 
The residue was purified by column chromatography (silica gel) employing a mixture of 
hexane–EtOAc (19:1) as eluent to give 76 mg (41% yield) of pure compound 16 as a 
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colorles oil: Rf 0.53 (hexane–AcOEt, 7:3); 1H NMR (500.13 MHz, CDCl3) δ 3.35 (t, J = 5.8 
Hz, 2H, H-1), 4.33 (t, J = 5.8 Hz, 2H, H-2), 6.95 (d, J = 9.2 Hz, 2H, H-2′), 6.99 (d, J = 8.4 
Hz, 2H, H-2″), 7.03 (d, J = 9.2 Hz, 2H, H-3′), 7.55 (d, J = 8.4 Hz, 2H, H-3″); 13C NMR 
(125.77 MHz, CDCl3) δ 33.2 (C-1), 66.4 (C-2), 111.6 (SCN), 116.1 (C-2′), 117.0 (C-3′), 
121.6 (C-2″), 127.1 (q, J = 3.8 Hz, C-3″), 149.7 (C-4′), 154.8 (C-1′), 161.2 (C-1″); 19F NMR 
(470.54 MHz, CDCl3) δ −61.70. HRMS (ESI) calcd for C16H12O2NSF3Na [M + Na]+ 
362.0439; found 362.0419.
β-Naphtyloxyphenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (17)
A mixture of 8 (889 mg, 3.73 mmol), 2-bromonaphtalene (111 mg, 0.54 mmol), copper(I) 
iodide (79 mg, 0.42 mmol), 2-picolinic acid (91.5 mg, 0.74 mmol), and potassium phosphate 
tribasic (1.53 g, 7.22 mmol) in methyl sulfoxide (6 mL) was treated according to the general 
procedure. The residue was purified by column chromatography (silica gel) employing 
hexane–EtOAc (9:1) as eluent to afford 244 mg (18% yield) of pure compound 17 as a 
colorless oil: Rf 0.55 (hexane–EtOAc, 7:3); 1H NMR (500.13 MHz, CDCl3) δ 1.53–1.68 (m, 
4H, H-4‴, H-5‴), 1.73–1.79 (m, 1H, H-3‴a), 1.85 (m, 1H, H-3‴b), 3.55 (m, 1H, H-6‴a), 
3.83 (ddd, J = 11.1, 6.4, 4.3 Hz, 1H, H-6‴b), 3.92 (ddd, J = 10.5, 8.9, 2.2 Hz, 1H, H-1a), 
4.07 (m, 1H, H-1b), 4.17 (m, 2H, H-2), 4.73 (t, J = 3.5 Hz, 1H, H-2‴), 6.96 (d, J = 9.1 Hz, 
2H, H-2′), 7.04 (d, J = 9.0 Hz, 2H, H-3′), 7.18 (d, J = 1.9 Hz, 1H, H-1″), 7.24 (dd, J = 9.0, 
2.5 Hz, 1H, H-3″), 7.37 (m, 1H, H-6″), 7.43 (ddd, J = 7.9, 7.1, 0.8 Hz, 1H, H-7″), 7.66 (d, J 
= 8.2 Hz, 1H, H-8″), 7.799 (d, J = 8.2 Hz, 1H, H-4″), 7.804 (d, J = 9.1 Hz, 1H, H-5″); 13C 
NMR (125.77 MHz, CDCl3) δ 19.4 (C-4‴), 25.4 (C-5‴), 30.5 (C-3‴), 62.2 (C-6‴), 65.9 
(C-1), 68.0 (C-2), 99.0 (C-2‴), 112.2 (C-1″), 115.9 (C-2′), 119.3 (C-3″), 121.0 (C-3′), 124.3 
(C-6″), 126.5 (C-8″), 127.0 (C-7″), 127.7 (C-5″), 129.8 (C-4″), 129.8 (C-10″), 134.3 (C-9″), 
150.2 (C-4′), 155.4 (C-1′), 156.4 (C-2″). HRMS (ESI) calc. for C23H24NaO4 [M+Na]+ 
387.1572; found 387.1558.
β-Naphtyloxyphenoxyethanol (18)
A solution of 17 (358 mg, 0.98 mmol) in methanol (10 mL) was treated with pyridinium p-
toluenesulfonate (20 mg) according to the general procedure. After the usual work-up, 
evaporation of the solvent yielded 266 mg of alcohol 18 (97% yield) as a white solid: Rf 
0.22 (hexane–EtOAc); 1H NMR (500.13 MHz, CDCl3) δ 3.99 (dist. t, J = 4.2 Hz, 2H, H-1), 
4.10 (dist. t, J = 4.5 Hz, 2H, H-2), 6.95 (d, J = 9.0 Hz, 2H, H-2′), 7.05 (d, J = 9.2 Hz, 2H, 
H-3′), 7.18 (d, J = 2.4 Hz, 1H, H-1″), 7.25 (dd, J = 9.0, 2.6 Hz, H-3″), 7.40 (ddd, J = 8.1, 
6.8, 1.3 Hz, 1H, H-6″), 7.43 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H, H-7″), 7.66 (dd, J = 8.1, 0.7 Hz, 
1H, H-8″), 7.80 (d, J = 8.2 Hz, 1H, H-4″), 7.81 (d, J = 9.0 Hz, 1H, H-5″); 13C NMR (125.77 
MHz, CDCl3) δ 61.6 (C-1), 69.7 (C-2), 112.4 (C-1″), 115.7 (C-2′), 119.4 (C-3″), 121.0 
(C-3′), 124.4 (C-6″), 126.5 (C-8″), 127.0 (C-7″), 127.7 (C-5″), 129.8 (C-4″), 129.8 (C-10″), 
134.3 (C-9″), 150.5 (C-4′), 155.1 (C-1′), 156.3 (C-2″). HRMS (ESI) calc. for C18H17O3 [M
+H]+ 281.1178; found 281.1166.
β-Naphtyloxyphenoxyethyl 4-Toluenesulfonate (19)
A solution of alcohol 18 (286 mg, 1.02 mmol) in pyridine (5 mL) was treated with tosyl 
chloride (547 mg, 2.87 mmol) at 0 °C as depicted in the general procedure. Purification of 
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the crude compound by column chromatography afforded 295 mg (67% yield) of tosylate 19 
as a white solid: Rf 0.50 (hexane–EtOAc, 7:3); 1H NMR (500.13 MHz, CDCl3) δ 2.45 (s, 
3H, CH3), 4.16 (m, 2H, H-1), 4.38 m, 2H, H-2), 6.81 (d, J = 9.1 Hz, 2H, H-2′), 7.00 (d, J = 
9.1 Hz, 2H, H-3′), 7.17 (d, J = 2.5 Hz, 1H, H-1″), 7.23 (dd, J = 8.8, 2.6 Hz, 1H, H-3″), 7.36 
(d, J = 8.0 Hz, 2H, H-3‴), 7.38 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H, H-6″), 7.44 (ddd, J = 8.1, 6.9, 
1.3 Hz, 1H, H-7″), 7.66 (dd, J = 8.2, 0.5 Hz, 1H, H-8″), 7.80 (d, J = 8.1 Hz, 1H, H-4″), 7.81 
(d, J = 9.0 Hz, 1H, H-5″), 7.84 (d, J = 8.3 Hz, 2H, H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 
21.7 (CH3), 66.1 (C-1), 68.1 (C-2), 112.5 (C-1″), 115.8 (C-2′), 119.4 (C-3″), 120.9 (C-3′), 
124.5 (C-6″), 126.5 (C-8″), 127.0 (C-7″), 127.7 (C-5″), 128.1 (C-2‴), 129.8 (C-4″), 129.9 
(C-10″), 129.9 (C-3‴), 132.9 (C-4‴), 134.3 (C-9″), 145.0 (C-1‴), 150.8 (C-4′), 154.4 (C-1′), 
158.9 (C-2″). HRMS (ESI) calc. for C25H22O5SNa [M+Na]+ 457.1086; found 457.1077.
β-Naphtyloxyphenoxyethyl Thiocyanate (20)
A solution of 19 (295 mg, 0.68 mmol) in anhydrous N,N-dimethylformamide (5 mL) was 
treated with potassium thiocyanate (350 mg, 3.60 mmol) according to the general procedure. 
The residue was purified by column chromatography (silica gel) employing hexane–EtOAc 
(9:1) as eluent to give 93.3 mg (43% yield) of pure 20 as a white solid: Rf 0.52 (hexane–
EtOAc, 7:3); mp 81–82 °C; 1H NMR (500.13 MHz, CDCl3) δ 3.35 (t, J = 5.8 Hz, 2H, H-1), 
4.32 (t, J = 5.8 Hz, 2H, H-2), 6.95 (d, J = 9.1 Hz, 2H, H-2′), 7.06 (d, J = 9.1 Hz, 2H, H-3′), 
7.20 (d, J = 2.4 Hz, 1H, H-1″), 7.24 (dd, J = 8.9, 2.5 Hz, 1H, H-3″), 7.38 (ddd, J = 8.1, 6.9, 
1.3 Hz, 1H, H-6″), 7.43 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H, H-7″), 7.67 (d, J = 8.2 Hz, 1H, H-8″), 
7.81 (d, J = 7.7 Hz, 1H, H-4″), 7.82 (d, J = 8.9 Hz, 1H, H-5″); 13C NMR (125.77 MHz, 
CDCl3) δ 33.4 (C-1), 66.4 (C-2), 111.8 (SCN), 112.6 (C-1″), 115.9 (C-2′), 121.0 (C-3′), 
124.5 (C-6″), 126.5 (C-8″), 127.0 (C-7″), 127.7 (C-5″), 129.83 (C-4″), 129.87 (C-5″a), 
134.3 (C-8″a), 151.1 (C-4′), 154.1 (C-1′), 156.0 (C-2″). HRMS (ESI) calcd for 
C19H15O2NSNa [M + Na]+ 344.0721; found 344.0711.
α-Naphtyloxyphenylethyl Tetrahydro-2H-pyran-2-yl Ether (21)
A mixture of 8 (724 mg, 3.04 mmol), 1-bromonaphtalene (840 mg, 4.08 mmol), copper (I) 
iodide (60.7 mg, 0.32 mmol), 2-picolinic acid (75.8 mg, 0.62 mmol) and potassium 
phosphate tribasic (1.33 g, 6.24 mmol) in dimethyl sulfoxide (6 mL) was treated as usual for 
48 h. The residue was purified by column chromatography (silica gel) employing hexane–
EtOAc (9:1) as eluent to give 322 mg (29% yield) of pure 21 as a colorless oil: Rf 0.56 
(hexane–EtOAc, 7:3); 1H NMR (500.13 MHz, CDCl3) δ 1.51–1.68 (m, 4H, H-4‴, H-5‴), 
1.72–1.78 (m, 1H, H-3‴a), 1.81–1.89 (m, 1H, H-3‴b), 3.55 (m, 1H, H-6‴a), 3.83 (ddd, J = 
11.1, 6.4, 4.3 Hz, 1H, H-6‴b), 3.90 (m, 1H, H-1a), 4.02 (ddd, J = 11.1, 5.0, 4.3 Hz, 1H, 
H-1b), 4.16 (m, 2H, H-2), 4.70 (t, J = 3.8 Hz, 1H, H-2‴), 6.79 (dd, J = 7.6, 0.8 Hz, 1H, 
H-2″), 6.94 (d, J = 9.2 Hz, 2H, H-2′), 7.02 (d, J = 9.2 Hz, 2H, H-3′), 7.33 (t, J = 7.8 Hz, 1H, 
H-3″), 7.52 (m, 2H, H-6″, H-7″), 7.58 (d, J = 8.6 Hz, 1H, H-4″), 7.85 (dd, J = 7.4, 1.9 Hz, 
1H, H-5″), 8.24 (d, J = 8.5 Hz, 1H, H-8″); 13C NMR (125.77 MHz, CDCl3) δ 19.4 (C-4‴), 
25.4 (C-5‴), 30.5 (C-3‴), 62.2 (C-6‴), 65.9 (C-1), 68.1 (C-2), 99.0 (C-2‴), 111.3 (C-2″), 
116.0 (C-2′), 120.5 (C-3′), 122.0 (C-4″), 122.4 (C-8″), 125.7 (C-3″), 126.2 (C-7″), 126.5 
(C-9″), 126.7 (C-6″), 127.6 (C-5″), 134.7 (C-10″), 149.7 (C-4′), 153.1 (C-1″), 155.2 (C-1′). 
HRMS (ESI) calcd for C23H24O4Na [M + Na]+ 387.1572; found 387.1563.
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α-Naphtyloxyphenylethanol (22)
A solution of 21 (322 mg, 0.89 mmol) in methanol (10 mL) was treated with pyridinium p-
toluene sulfonate (20 mg) according to the general method to afford 229 mg (92% yield) of 
22 as a colorless oil: Rf 0.24 (hexane–EtOAc, 7:3); 1H NMR (500.13 MHz, CDCl3) δ 3.98 
(dist. t, J = 4.3 Hz, 2H, H-1), 4.09 (dist. t, J = 4.1 Hz, 2H, H-2), 6.80 (d, J = 7.5 Hz, 1H, 
H-2″), 6.93 (d, J = 9.0 Hz, 2H, H-2′), 7.03 (d, J = 9.0 Hz, 2H, H-3′), 7.34 (t, J = 7.9 Hz, 1H, 
H-3″), 7.52 (m, 2H, H-6″, H-7″), 7.56 (d, J = 8.3 Hz, 1H, H-4″), 7.86 (dd, J = 7.3, 1.6 Hz, 
1H, H-5″), 8.28 (dd, J = 8.0, 1.5 Hz, 1H, H-8″); 13C NMR (125.77 MHz, CDCl3) δ 61.5 
(C-1), 69.7 (C-2), 111.5 (C-2″), 115.7 (C-2′), 120.6 (C-3′), 122.0 (C-4″), 122.5 (C-8″), 125.7 
(C-3″), 125.8 (C-7″), 126.4 (C-9″), 126.6 (C-6″), 127.7 (C-5″), 134.8 (C-10″), 151.1 (C-4′), 
154.3 (C-1″), 154.9 (C-1′). HRMS (ESI) calcd for C18H16O3Na [M+Na]+ 303.0997; found 
303.1005.
α-Naphtyloxyphenylethyl 4-Toluenesulfonate (23)
To a solution of alcohol 22 (229 mg, 0.82 mmol) in pyridine (5 mL) was added p-
toluenesulfonyl chloride (517 mg, 2.71 mmol) at 0 °C. After the usual work up, purification 
of the product afforded 323 mg (91% yield) of tosylate 23 as a white solid: Rf 0.48 (hexane–
EtOAc, 7:3); 1H NMR (500.13 MHz, CDCl3) δ 2.45 (s, 3H, CH3), 4.15 (m, 2H, H-1), 4.37 
(m, 2H, H-2), 6.788 (d, J = 6.8 Hz, 1H, H-2″), 6.790 (d, J = 9.1 Hz, 2H, H-2′), 6.98 (d, J = 
9.1 Hz, 2H, H-3′), 7.33 (t, J = 8.2 Hz, 1H, H-3″), 7.35 (d, J = 8.0 Hz, 2H, H-3‴), 7.52 (m, 
2H, H-6″, H-7″), 7.57 (d, J = 8.3 Hz, 1H, H-4″), 7.83 (d, J = 8.4 Hz, 2H, H-2‴), 7.86 (dd, J 
= 7.3, 1.8 Hz, 1H, H-5″), 8.26 (dd, J = 7.7, 1.3 Hz, 1H, H-8″). HRMS (ESI) calcd for 
C25H22O5SNa [M + Na]+ 457.1086; found 457.1082.
α-Naphtyloxyphenylethyl Thiocyanate (24)
A solution of tosylate 23 (323 mg, 1.03 mmol) in N,N-dimethylformamide (6 mL) was 
treated with potassium thiocyanate (581 mg, 5.98 mmol) following the general procedure. 
The residue was purified by column chromatography (silica gel) employing a mixture of 
hexane–EtOAc (19:1) as eluent to afford 140 mg (43% yield) of pure 24 as a white solid: Rf 
0.54 (hexane–AcOEt, 7:3); mp 95–96 °C; 1H NMR (500.13 MHz, CDCl3) δ 3.35 (t, J = 5.8 
Hz, 2H, H-1), 4.32 (t, J = 5.8 Hz, 2H, H-2), 6.83 (d, J = 7.6 Hz, 1H, H-2″), 6.93 (d, J = 9.1 
Hz, 2H, H-2′), 7.04 (d, J = 9.1 Hz, 2H, H-3′), 7.35 (t, J = 7.9 Hz, 1H, H-3″), 7.52 (m, 2H, 
H-6″, H-7″), 7.58 (d, J = 8.2 Hz, 1H, H-4″), 7.87 (dd, J = 7.4, 1.9 Hz, 1H, H-5″), 8.26 (dd, J 
= 8.0, 1.5 Hz, 1H, H-8″); 13C NMR (125.77 MHz, CDCl3) δ 33.3 (C-1), 66.4 (C-2), 111.7 
(SCN), 111.8 (C-2″), 116.0 (C-2′), 120.5 (C-3′), 122.0 (C-4″), 122.8 (C-8″), 125.7 (C-3″), 
125.9 (C-7″), 126.4 (C-9″), 126.6 (C-6″), 127.7 (C-5″), 134.9 (C-10″), 151.8 (C-4′), 153.9 
(C-1″), 154.0 (C-1′). HRMS (ESI) calcd for C19H15O2NSNa [M+Na]+ 344.0721; found 
344.0702.
4-(Pyridin-2-yloxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (26)
A mixture of 25 (1.40 g, 4.02 mmol), 2-hydroxypyridine (450 mg, 4.73 mmol), copper (I) 
iodide (73.3 mg, 0.38 mmol), 2-picolinic acid (91.0 mg, 0.74 mmol), and potassium 
phosphate tribasic (1.74 g, 8.20 mmol) in methyl sulfoxide (6 mL) was treated according to 
the general procedure for 8 days. The product was purified by column chromatography 
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(silica gel) eluting with a mixture of hexane–EtOAc (3:7) to give 607 mg (48% yield) of 
pure 26 as a colorless oil: Rf 0.09 (hexane–EtOAc, 1:1); 1H NMR (500.13 MHz, CDCl3) δ 
1.52–1.65 (m, 4H, H-4‴, H-5‴), 1.72–1.78 (m, 1H, H-3‴a), 1.81–1.86 (m, 1H, H-3‴b), 3.54 
(m, 1H, H-6‴a), 3.84 (ddd, J = 11.2, 6.4, 4.4 Hz, 1H, H-6‴b), 3.91 (ddd, J = 11.2, 8.2, 3.0 
Hz, 1H, H-1a), 4.07 (ddd, J = 11.2, 4.8, 4.2 Hz, 1H, H-1b), 4.18 (m, 2H, H-2), 4.72 (t, J = 
3.6 Hz, 1H, H-2‴), 6.22 (dt, J = 6.7, 0.9 Hz, 1 H, H-4″), 6.64 (d, J = 9.2 Hz, 1H, H-6″), 7.02 
(d, J = 9.0 Hz, 2H, H-2′), 7.28 (d, J = 9.0 Hz, 2H, H-3′), 7.32 (dd, J = 6.8, 2.1 Hz, 1H, 
H-3″), 7.39 (ddd, J = 9.2, 6.6, 2.1 Hz, 1H, H-5″); 13C NMR (125.77 MHz, CDCl3) δ 19.2 
(C-4‴), 25.3 (C-5‴), 30.4 (C-3‴), 62.1 (C-6‴), 65.6 (C-1), 67.7 (C-2), 98.9 (C-2‴), 105.7 
(C-6″), 115.1 (C-2′), 121.6 (C-4″), 127.4 (C-3′), 133.7 (C-4′), 138.2 (C-5″), 139.8 (C-3″), 
158.6 (C-1′), 162.6 (C-1″). HRMS (ESI) calcd. for C18H21NO4Na [M+Na]+ 338.1368; 
found 338.1365.
4-(Pyridin-2-yloxy)phenoxyethanol (27)
A solution of 26 (607 mg, 1.92 mmol) in methanol (10 mL) was treated with pyridinium p-
toluenesulfonate (20 mg) and the mixture was stirred at room temperarture for 4 h. After the 
usual work up, the product was purified by column chromatography (silica gel) employing 
EtOAc as eluent to afford 266 mg (60% yield) of pure alcohol 27 as a white solid: Rf 0.09 
(AcOEt); mp 150 °C; 1H NMR (500.13 MHz, CDCl3) δ 3.99 (m, 2H, H-1), 4.13 (dist. t, J = 
4.6 Hz, 2H, H-2), 6.22 (dt, J = 6.7, 1.4 Hz, 1H, H-4″), 6.65 (dq, J = 9.3, 0.7 Hz, 1H, H-6″), 
7.02 (d, J = 9.0 Hz, 2H, H-2′), 7.31 (d, J = 8.9 Hz, 2H, H-3′), 7.32 (ddd, J = 6.5, 2.2, 0.6 Hz, 
1H, H-3″), 7.39 (ddd, J = 9.2, 6.6, 2.2 Hz, 1H, H-5″); 13C NMR (125.77 MHz, CDCl3) δ 
61.4 (C-1), 69.5 (C-2), 105.8 (C-6″), 115.2 (C-2′), 121.9 (C-4″), 127.7 (C-3′), 138.2 (C-5″), 
139.8 (C-3″), 158.4 (C-1′), 163.8 (C-1″). 105.7 (C-6″), 115.1 (C-2′), 121.6 (C-4″), 127.4 
(C-3′), 133.7 (C-4′), 138.2 (C-5″), 139.8 (C-3″), 158.6 (C-1′), 162.6 (C-1″). HRMS (ESI) 
calcd. for C13H14NO3 [M+H]+ 232.0974; found 232.0978.
4-(Pyridin-2-yloxy)phenoxyethyl 4-Toluenesulfonate (28)
A solution of alcohol 27 (122 mg, 0.53 mmol) in pyridine (2 mL) was treated with tosyl 
chloride (352 mg, 1.85 mmol) at 0 °C. The reaction was quenched as depicted for the 
preparation of 13 to afford 183 mg (90% yield) of pure 28 as a white solid: Rf 0.39 
(AcOEt); 1H NMR (500.13 MHz, CDCl3) δ 2.46 (s, 3H, CH3), 4.18 (m, 2H, H-1), 4.39 (m, 
2H, H-2), 6.22 (dt, J = 6.7, 1.3 Hz, 1H, H-4″), 6.64 (dq, J = 9.3, 0.6 Hz, 1H, H-6″), 6.88 (d, 
J = 8.9 Hz, 2H, H-2′), 7.27 (d, J = 8.9 Hz, 2H, H-3′), 7.30 (ddd, J = 6.9, 2.0, 0.5 Hz, 1H, 
H-3″), 7.36 (d, J = 7.9 Hz, 2H, H-3‴), 7.39 (ddd, J = 9.0, 6.6, 2.3 Hz, 1H, H-5″), 7.83 (d, J = 
8.4 Hz, 2H, H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.7 (CH3), 65.8 (C-1), 67.9 (C-2), 
105.8 (C-6″), 115.2 (C-2′), 121.8 (C-4″), 127.7 (C-3′), 128.0 (C-2‴), 129.9 (C-3‴), 134.5 
(C-4′), 132.8 (C-4‴), 138.1 (C-5″), 139.8 (C-3″), 145.1 (C-1‴), 157.8 (C-1′), 162.6 (C-1″). 
HRMS (ESI) calcd. for C20H20N2O5S [M+H]+ 386.1062; found 386.1055.
4-(Pyridin-2-yloxy)phenoxyethyl Thiocyante (29)
A solution of compound 28 (136 mg, 0.35 mmol) in anhydrous N,N-dimethylformamide (2 
mL) was treated with potassium thiocyanate (200 mg, 2.06 mmol) according to the general 
method. The product was purified by column chromatography (silica gel) employing a 
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mixture of hexane-EtOAc (1:1) as eluent to yield 56.9 mg (61% yield) of thiocyanate 29 as a 
white solid: Rf 0.38 (AcOEt); 1H NMR (500.13 MHz, CDCl3) δ 3.36 (t, J = 5.8 Hz, 2H, 
H-1), 4.36 (t, J = 5.8 Hz, 2H, H-2), 6.23 (dt, J = 6.7, 1.3 Hz, 1H, H-4″), 6.65 (dq, J = 9.3, 0.7 
Hz, 1H, H-6″), 7.02 (d, J = 9.0 Hz, 2H, H-2′), 7.33 (d, J = 9.0 Hz, 2H, H-3′), 7.31 (ddd, J = 
7.0, 1.8, 0.7 Hz, 1H, H-3″), 7.39 (ddd, J = 9.2, 6.6, 2.1 Hz, 1H, H-5″); 13C NMR (125.77 
MHz, CDCl3) δ 33.1 (C-1), 66.2 (C-2), 105.9 (C-6″), 111.6 (SCN), 115.3 (C-2′), 121.9 
(C-4″), 127.9 (C-3′), 134.8 (C-4′), 138.1 (C-5″), 139.9 (C-3″), 157.6 (C-1′), 162.6 (C-1″). 
HRMS (ESI) calcd. for C14H13N2O2S [M+H]+ 273.0698; found 2.0703.
3-(2-Chlorophenoxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (31)
A mixture of compound 30 (927 mg, 2.6 mmol), 2-chlorophenol (411 mg, 3.2 mmol), 
copper (I) iodide (50.6 mg, 0.27 mmol), 2-picolinic acid, (65.5 mg, 0.53 mmol), and 
potassium phosphate tribasic (1.129 g, 5.3 mmol) was evacuated and back-filled with argon 
as described for the preparation of 9. The product was purified by column chromatography 
(silica gel) employing hexane–EtOAc (24:1) as eluent to afford 475 mg (51% yield) of pure 
31 as a colorless oil: Rf 0.47 (hexane–EtOAc; 4:1); 1H NMR (500.13 MHz, CDCl3) δ 1.50–
1.65 (m, 4H, H-4‴, H-5‴), 1.70–1.76 (m, 1H, H-3‴a), 1.79–1.86 (m, 1H, H-3‴b), 3.52 (m, 
1H, H-6‴a), 3.80 (ddd, J = 11.2, 6.4, 4.2 Hz, 1H, H-6‴b), 3.88 (ddd, J = 11.2, 8.2, 3.1 Hz, 
1H, H-1a), 4.07 (m, 1H, H-1b), 4.12 (m, 2H, H-2), 4.69 (t, J = 3.6 Hz, 1H, H-2‴), 6.54 (m, 
2H, H-4′, H-6′), 6.55 (t, J = 2.3 Hz, 1H, H-2′), 7.02 (dt, J = 8.0, 1.5 Hz, 1H, H-6″), 7.09 (dt, 
J = 7.7, 1.5 Hz, 1H, H-4″), 7.21 (t, J = 8.0 Hz, 1H, H-5′), 7.22 (m, 1H, H-5″), 7.45 (dd, J = 
8.0, 1.6 Hz, 1H, H-3″); 13C NMR (125.77 MHz, CDCl3) δ 19.4 (C-4‴), 25.4 (C-5‴), 30.5 
(C-3‴), 62.2 (C-6‴), 65.7 (C-1), 67.6 (C-2), 99.0 (C-2‴), 104.8 (C-2′), 109.6 (C-6′), 110.2 
(C-4′), 121.2 (C-6″), 124.8 (C-4″), 126.0 (C-2″), 127.9 (C-5″), 130.1 (C-3″), 130.8 (C-5′), 
152.2 (C-1″), 158.1 (C-3′), 160.2 (C-1′). HRMS (ESI) calcd for C19H21O4ClNa [M+Na]+ 
371.1026; found 371.1023.
3-(2-Chlorophenoxy)phenoxyethanol (36)
A solution of compound 31 (475 mg, 1.4 mmol) in methanol (75 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg) at 0 °C. The reaction mixture was stirred at room 
temperature overnight. After the usual work up, the residue was purified by column 
chromatography eluting with hexane–EtOAc (4:1) to give 252 mg (70% yield) of pure 
alcohol 36 as a colorless oil: Rf 0.05(hexane–EtOAc; 4:1); 1H NMR (500.13 MHz, CDCl3) δ 
3.95 (dist. t, J = 4.5 Hz, 2H, H-1), 4.06 (dist. t, J = 4.5 Hz, 2H, H-2), 6.54 (t, J = 2.2 Hz, 1H, 
H-4′), 6.56 (ddd, J = 8.1, 2.3, 0.9 Hz, 1H, H-6′), 6.66 (ddd, J = 8.2, 2.3, 0.8 Hz, 1H, H-2′), 
7.03 (dd, J = 8.1, 1.5 Hz, 1H, H-6″), 7.10 (ddd, J = 7.7, 7.5, 1.5 Hz, 1H, H-4″), 7.22 (t, J = 
8.0 Hz, 1H, H-5′), 7.24 (m, 1H, H-5″), 7.46 (dd, J = 8.0, 1.6 Hz, 1H, H-3″); 13C NMR 
(125.77 MHz, CDCl3) δ 61.4 (C-1), 67.3 (C-2), 104.5 (C-2′), 109.3 (C-6′), 110.3 (C-4′), 
121.3 (C-6″), 125.0 (C-4″), 126.1 (C-2″), 128.0 (C-5″), 130.3 (C-3″), 130.8 (C-5′), 152.2 
(C-1″), 158.1 (C-3′), 160.3 (C-1′). HRMS (ESI) calcd for C14H14O3Cl [M+H]+ 265.0631; 
found 265.0633.
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3-(2-Chlorophenoxy)phenoxyethyl 4-Toluenesulfonate (41)
A solution of alcohol 36 (253 mg, 0.95 mmol) in pyridine (3 mL) was treated with p-
toluenesulfonyl chloride (546 mg, 2.9 mmol) according to the general method. The product 
was purified by column chromatography (silica gel) employing a mixture of hexane–EtOAc 
(9:1) as eluent to afford 226 mg (66% yield) of tosylate 41 as a colorless oil. Rf 0.25 
(hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 2.44 (s, 3H, CH3), 4.11 (m, 2H, 
H-1), 4.35 (m, 2H, H-2), 6.39 (t, J = 2.3 Hz, 1H, H-2′), 6.53 (m, 2H, H-4′, H-6′), 7.00 (dd, J 
= 8.1, 1.5 Hz, 1H, H-6″), 7.11 (dt, J = 7.7, 1.5 Hz, 1H, H-4″), 7.18 (t, J = 8.2 Hz, 1H, H-5′), 
7.24 (ddd, J = 8.1, 7.5, 1.6 Hz, 1H, H-5″), 7.32 (d, J = 8.0 Hz, 2H, H-3‴), 7.46 (dd, J = 8.0, 
1.6 Hz, 1H, H-3″), 7.81 (d, J = 8.4 Hz, 2H, H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.6 
(CH3), 65.5 (C-1), 68.0 (C-2), 104.6 (C-2′), 109.2 (C-6′), 110.6 (C-4′), 121.2 (C-6″), 125.0 
(C-4″), 127.99 (C-5″), 128.02 (C-2‴), 129.8 (C-3‴), 130.2 (C-3″), 130.9 (C-5′), 132.9–
145.0 (C-1‴), 152.0 (C-1″), 158.2 (C-3′), 159.3 (C-1′). HRMS (ESI) calcd for 
C21H19O5SClNa [M+Na]+ 441.0539; found 441.0547.
3-(2-Chlorophenoxy)phenoxyethyl Thiocyanate (46)
A solution of tosylate 41 (226 mg, 0.54 mmol) in anhydrous N,N-dimethylformamide (3 
mL) was treated with potassium thiocyanate (262 mg, 2.7 mmol). The reaction mixture was 
heated at 100 °C for 3 h. After the usual work up, the residue was purified by column 
chromatography (silica gel) eluting with hexane–EtOAc (19:1) to give 15.8 mg (10% yield) 
of pure 46 as a colorless oil: Rf 0.38 (hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) 
δ 3.32 (t, J = 5.8 Hz, 2H, H-1), 4.29 (t, J = 5.8 Hz, 2H, H-2), 6.55 (t, J = 2.3 Hz, 1H, H-3′), 
6.57 (ddd, J = 8.2, 2.1, 0.8 Hz, 1H, H-4′), 6.67 (ddd, J = 8.3, 2.4, 0.7 Hz, 1H, H-6′), 7.03 
(dd, J = 8.2, 1.5 Hz, 1H, H-6″), 7.11 (dt, J = 7.7, 1.4 Hz, 1H, H-4″), 7.24 (t, J = 8.2 Hz, 1H, 
H-H-5′), 7.24 (m, 1H, H-5″), 7.47 (dd, J = 8.0, 1.6 Hz, 1H, H-3″); 13C NMR (125.77 MHz, 
CDCl3) δ 33.2 (C-1), 65.9 (C-2), 104.6 (C-2′), 109.3 (C-6′), 110.8 (C-4′), 111.6 (SCN), 
121.4 (C-6″), 125.1 (C-4″), 126.2 (C-2″), 128.0 (C-5″), 130.4 (C-5′), 130.9 (C-5′), 151.9 
(C-1″), 158.4 (C-3′), 159.1 (C-1′). HRMS (ESI) calcd for C15H12O2NSClNa [M+Na]+ 
328.0175; found 328.0169.
3-(3-Chlorophenoxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (32)
A mixture of compound 30 (959 mg, 2.7 mmol), 3-chlorophenol (708 mg, 5.5 mmol), 
copper (I) iodide (52.4 mg, 0.27 mmol), 2-picolinic acid, (67.8 mg, 0.55 mmol), and 
potassium phosphate tribasic (1.169 g, 5.5 mmol) under the conditions depicted for the 
preparation of 9. The reaction mixture was stirred vigorously at 90 °C for 21 days. The 
product was purified by column chromatography (silica gel) employing hexane–EtOAc 
(24:1) as eluent to afford 826 mg (86% yield) of pure 32 as a colorless oil: Rf 0.76 (hexane–
EtOAc; 3:2); 1H NMR (500.13 MHz, CDCl3) δ 1.52–1.65 (m, 4H, H-4‴, H-5‴), 1.72–1.76 
(m, 1H, H-3‴a), 1.81–1.84 (m, 1H, H-3‴b), 3.55 (m, 1H, H-6‴a), 3.80 (ddd, J = 10.7, 6.6, 
3.8 Hz, 1H, H-6‴b), 3.91 (ddd, J = 11.1, 8.7, 2.4 Hz, 1H, H-1a), 4.07 (m, 1H, H-1b), 4.12 
(m, 2H, H-2), 4.72 (t, J = 3.3 Hz, 1H, H-2‴), 6.61 (t, J = 2.3 Hz, 1H, H-2′), 6.72 (m, 2H, 
H-4′, H-6′), 6.90 (dd, J = 8.0, 1.3 Hz, 1H, H-6″), 7.00 (t, J = 2.0 Hz, 1H, H-2″), 7.09 (m, 1H, 
H-4″), 7.25 (t, J = 8.2 Hz, 2H, H-5′, H-5″); 13C NMR (125.77 MHz, CDCl3) δ 19.2 (C-4‴), 
25.3 (C-5‴), 30.4 (C-3‴), 62.3 (C-6‴), 65.8 (C-1), 67.5 (C-2), 99.1 (C-2‴), 106.1 (C-2′), 
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110.2 (C-6′), 111.6 (C-4′), 116.8 (C-6″), 118.9 (C-2″), 123.2 (C-4″), 130.2 (C-5″), 130.4 
(C-5′), 134.6 (C-3″), 157.4 (C-1″), 158.0 (C-3′), 160.2 (C-1′).
3-(3-Chlorophenoxy)phenoxyethanol (37)
A solution of compound 32 (581 mg, 1.7 mmol) in methanol (75 mL) was treated with 
pyridinium p-toluenesulfonate (30 mg). The reaction mixture was stirred at room 
temperature overnight and was quenched as described for the preparation of 6. The product 
was purified by column chromatography eluting with hexane-EtOAc (86:14) to give 302 mg 
(55% yield) of pure alcohol 37 as a colorless oil: Rf 0.14 (hexane–EtOAc; 4:1); 1H NMR 
(500.13 MHz, CDCl3) δ 3.98 (m, 2H, H-1), 4.09 (t, J = 4.1 Hz, 2H, H-2), 6.62 (t, J = 2.3 Hz, 
1H, H-2′), 6.65 (dd, J = 8.1, 1.6 Hz, 1H, H-4′), 6.74 (dd, J = 8.2, 2.1 Hz, 1H, H-6′), 6.93 (dd, 
J = 8.3, 1.6 Hz, 1H, H-6″), 7.03 (t, J = 2.1 Hz, 1H, H-2″), 7.11 (dd, J = 7.9, 0.7 Hz, 1H, 
H-4″), 7.28 (dt, J = 8.2, 2.6 Hz, 2H, H-5′, H-5″); 13C NMR (125.77 MHz, CDCl3) δ 61.4 
(C-1), 69.3 (C-2), 105.9 (C-2′), 110.0 (C-6′), 111.8 (C-4′), 117.0 (C-6″), 119.1 (C-2″), 123.4 
(C-4″), 130.4 (C-5″), 130.5 (C-5′), 135.0 (C-3″), 157.6 (C-1″), 157.9 (C-3′), 160.0 (C-1′). 
HRMS (ESI) calcd for C14H13O3ClNa [M+Na]+ 287.0451; found 287.0441.
3-(3-Chlorophenoxy)phenoxyethyl 4-Toluenesulfonate (42)
To a solution of 37 (368 mg, 1.39 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (796 mg, 4.18 mmol) following the method of the preparation described for 11. The 
product was purified by column chromatography (silica gel) eluting with hexane–EtOAc 
(97:3) to give 290 mg (50% yield) of pure 42 as a colorless oil: Rf 0.19 (hexane–EtOAc, 
4:1); 1H NMR (500.13 MHz, CDCl3) δ 2.43 (s, 3H, CH3), 4.12 (m, 2H, H-1), 4.36 (m, 2H, 
H-2), 6.42 (t, J = 2.3 Hz, 1H, H-2′), 6.57 (ddd, J = 8.3, 2.4, 0.7 Hz, 1H, H-4′), 6.61 (ddd, J = 
8.2, 2.3, 0.8 Hz, 1H, H-6′), 6.88 (ddd, J = 8.3, 2.4, 0.9 Hz, 1H, H-6″), 6.97 (t, J = 2.2 Hz, 
1H, H-2″), 7.08 (ddd, J = 8.0, 1.9, 0.9 Hz, 1H, H-4″), 7.24 (m, 2H, H-5′, H-5″), 7.32 (d, J = 
8.0 Hz, 2H, H-3‴), 7.81 (d, J = 8.3 Hz, 2H, H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.6 
(CH3), 65.5 (C-1), 67.9 (C-2), 106.0 (C-2′), 109.8 (C-6′), 112.1 (C-4′), 116.9 (C-6″), 119.0 
(C-2″), 123.5 (C-4″), 128.0 (C-2‴), 129.8 (C-3‴), 130.4 (C-5″), 130.5 (C-5′), 132.8 (C-4‴), 
135.0 (C-3″), 145.0 (C-1‴), 157.5 (C-1″), 157.9 (C-3′), 159.4 (C-1′). HRMS (ESI) calcd for 
C21H19O5SClNa [M+Na]+ 441.0539; found 441.0543.
3-(3-Chlorophenoxy)phenoxyethyl Thiocyanate (47)
To a solution of 12 (252 mg, 0.60 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (293 mg, 3.0 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (91:9) to afford 92.3 mg (50% yield) of 47 as a colorless oil: Rf 
0.36 (hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 3.33 (t, J = 5.8 Hz, 2H, H-1), 
4.30 (t, J = 5.8 Hz, 2H, H-2), 6.59 (t, J = 2.3 Hz, 1H, H-2′), 6.66 (ddd, J = 8.2, 2.3, 0.8 Hz, 
1H, H-4′), 6.71 (ddd, J = 8.3, 2.4, 0.7 Hz, 1H, H-6′), 6.91 (ddd, J = 8.3, 2.4, 0.9 Hz, 1H, 
H-6″), 7.00 (t, J = 2.1 Hz, 1H, H-2″), 7.09 (ddd, J = 8.0, 1.9, 0.9 Hz, 1H, H-4″), 7.30 (m, 
2H, H-5′, H-5″); 13C NMR (125.77 MHz, CDCl3) δ 33.2 (C-1), 65.9 (C-2), 106.1 (C-2′), 
109.9 (C-6′), 111.6 (SCN), 112.4 (C-4′), 117.0 (C-6″), 119.1 (C-2″) 123.6 (C-4″), 130.5 
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(C-5″), 130.6 (C-5′), 135.1 (C-3″), 157.7 (C-1″), 157.8 (C-3′), 159.2 (C-1′). HRMS (ESI) 
calcd for C15H12O2SNClNa [M + Na]+ 328.0175; found 328.0177.
3-(4-Chlorophenoxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (33)
A mixture of compound 30 (810 mg, 2.3 mmol), 4-chlorophenol (598 mg, 4.6 mmol), 
copper (I) iodide (44.4 mg, 0.23 mmol), 2-picolinic acid, (57.4 mg, 0.47 mmol), and 
potassium phosphate tribasic (987 mg, 4.6 mmol) was treated according to the general 
procedure and stirred at 90 °C for 19 days. The product was purified by column 
chromatography (silica gel) employing hexane–EtOAc (24:1) as eluent to afford 417 mg 
(51% yield) of pure 33 as a colorless oil: Rf 0.34 (hexane–EtOAc; 3:2); 1H NMR (500.13 
MHz, CDCl3) δ 1.52–1.69 (m, 4H, H-4‴, H-5‴), 1.73–1.79 (m, 1H, H-3‴a), 1.82–1.88 (m, 
1H, H-3‴b), 3.55 (m, 1H, H-6‴a), 3.82 (ddd, J = 11.2, 6.4, 4.1 Hz, 1H, H-6‴b), 3.91 (ddd, J 
= 11.2, 8.3, 3.0 Hz, 1H, H-1a), 4.06 (m, 1H, H-1b), 4.14 (m, 2H, H-2), 4.72 (t, J = 3.6 Hz, 
1H, H-2‴), 6.60 (m, 2H, H-2′, H-4′), 6.79 (d, J = 9.0 Hz, 1H, H-6′), 6.97 (d, J = 9.0 Hz, 2H, 
H-3″), 7.21 (d, J = 8.9 Hz, 1H, H-6′), 7.22 (t, J = 8.5 Hz, 1H, H-5′), 7.31 (d, J = 9.1 Hz, 2H, 
H-2″); 13C NMR (125.77 MHz, CDCl3) δ 19.4 (C-4‴), 25.4 (C-5‴), 30.5 (C-3‴), 62.2 
(C-6‴), 65.7 (C-1), 67.6 (C-2), 99.0 (C-2‴), 105.7 (C-2′), 109.9 (C-6′), 111.2 (C-4′), 120.2 
(C-2″), 128.3 (C-4″), 129.5 (C-5′), 129.7 (C-3″), 155.7 (C-1″), 158.0 (C-1′), 160.3 (C-3′). 
HRMS (ESI) calcd for C19H21O4ClNa [M+Na]+ 371.1026; found 371.1002.
3-(4-Chlorophenoxy)phenoxyethanol (38)
A solution of compound 33 (417 mg, 1.2 mmol) in methanol (75 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg). The reaction mixture was stirred at room 
temperature overnight and was quenched as described for the preparation of 11. The product 
was purified by column chromatography eluting with hexane–EtOAc (9:1) to give 219 mg 
(69% yield) of pure alcohol 38 as a colorless oil: Rf 0.11 (hexane–EtOAc; 8:2); 1H NMR 
(500.13 MHz, CDCl3) δ 1.98 (t, J = 6.3, 1H, -OH), 3.95 (dt, J = 6.0, 4.6 Hz, 2H, H-1), 4.05 
(dist. t, J = 4.5 Hz, 2H, H-2), 6.56 (t, J = 2.3 Hz, 1H, H-2′), 6.60 (ddd, J = 8.1, 2.2, 0.7 Hz, 
1H, H-4′), 6.68 (ddd, J = 8.3, 2.4, 0.7 Hz, 1H, H-6′), 6.95 (d, J = 9.0 Hz, 2H, H-3″), 7.23 (t, 
J = 8.2 Hz, 1H, H-5′), 7.29 (d, J = 9.0 Hz, 2H, H-2″); 13C NMR (125.77 MHz, CDCl3) δ 
61.4 (C-1), 69.3 (C-2), 105.5 (C-2′), 109.6 (C-6′), 111.4 (C-4′), 120.4 (C-2″), 128.5 (C-4″), 
129.7 (C-5′), 130.3 (C-3″), 155.6 (C-1″), 158.2 (C-1′), 160.0 (C-3′). HRMS (ESI) calcd for 
C14H13O3ClNa [M+Na]+ 287.0451; found 287.0450.
3-(4-Chlorophenoxy)phenoxyethyl 4-Toluenesulfonate (43)
To a solution of 8 (219 mg, 0.83 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (474 mg, 2.48 mmol) following the method of preparation described for 12. The 
product was purified by column chromatography (silica gel) eluting with hexane–EtOAc 
(47:3) to give 269 mg (78% yield) of pure 13 as a colorless oil: Rf 0.25 (hexane–EtOAc, 
4:1); 1H NMR (500.13 MHz, CDCl3) δ 2.43 (s, 3H, CH3), 4.11 (m, 2H, H-1), 4.35 (m, 2H, 
H-2), 6.41 (t, J = 2.3 Hz, 1H, H-2′), 6.55 (ddd, J = 8.3, 2.4, 0.7 Hz, 1H, H-4′), 6.58 (ddd, J = 
8.2, 2.2, 0.7 Hz, 1H, H-6′), 6.93 (d, J = 9.0 Hz, 2H, H-3″), 7.20 (t, J = 8.3 Hz, 1H, H-5′), 
7.30 (d, J = 9.0 Hz, 2H, H-2″), 7.33 (d, J = 8.0 Hz, 2H, H-3‴), 7.81 (d, J = 8.4 Hz, 2H, 
H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.6 (CH3), 65.5 (C-1), 67.9 (C-2), 105.6 (C-2′), 
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109.5 (C-6′), 111.6 (C-4′), 120.3 (C-2″), 128.0 (C-2‴), 128.5 (C-4″), 129.7 (C-5′), 129.8 
(C-3‴), 130.3 (C-3″), 132.8 (C-4‴), 145.0 (C-1‴), 155.5 (C-1″), 158.1 (C-1′), 159.3 (C-3′). 
HRMS (ESI) calcd for C21H20O5ClS [M+H]+ 419.0720; found 419.0717.
3-(4-Chlorophenoxy)phenoxyethyl Thiocyanate (48)
To a solution of 13 (269 mg, 0.64 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (319 mg, 3.2 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (24:1) to afford 104 mg (53% yield) of 48 as a colorless oil: Rf 
0.18 (hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 3.32 (t, J = 5.8 Hz, 2H, H-1), 
4.29 (t, J = 5.8 Hz, 2H, H-2), 6.56 (t, J = 2.3 Hz, 1H, H-2′), 6.62 (dd, J = 7.9, 2.0 Hz, 1H, 
H-4′), 6.68 (dd, J = 8.3, 2.4 Hz, 1H, H-6′), 6.96 (d, J = 9.0 Hz, 2H, H-3″), 7.25 (t, J = 8.3 
Hz, 1H, H-5′), 7.30 (d, J = 9.0 Hz, 2H, H-2″); 13C NMR (125.77 MHz, CDCl3) δ 33.2 (C-1), 
65.9 (C-2), 105.6 (C-2′), 109.6 (C-6′), 111.6 (SCN), 111.9 (C-4′), 120.4 (C-2″), 128.6 
(C-4″), 129.8 (C-5′), 130.5 (C-3″), 155.4 (C-1″), 158.3 (C-1′), 159.2 (C-3′). HRMS (ESI) 
calcd for C15H13O2NSCl [M+H]+ 306.0356; found 306.0365.
3-(2-Methoxyphenoxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (34)
To a mixture of compound 30 (939 mg, 2.7 mmol), 2-methoxyphenol (670 mg, 5.4 mmol), 
copper (I) iodide (51.4 mg, 0.27 mmol), 2-picolinic acid, (66.4 mg, 0.54 mmol), and 
potassium phosphate tribasic (1.148 g, 5.4 mmol) was added dimethyl sulfoxide (3.0 mL) 
and the reaction mixture was stirred at 90 °C for 3 days according to the general method. 
The product was purified by column chromatography (silica gel) employing hexane–EtOAc 
(47:3) as eluent to afford 628 mg (68% yield) of pure 34 as a colorless oil: Rf 0.35 (hexane–
EtOAc; 4:1); 1H NMR (500.13 MHz, CDCl3) δ 1.50–1.65 (m, 4H, H-4‴, H-5‴), 1.70–1.76 
(m, 1H, H-3‴a), 1.79–1.85 (m, 1H, H-3‴b), 3.51 (m, 1H, H-6‴a), 3.79 (ddd, J = 11.0, 6.5, 
4.4 Hz, 1H, H-6‴b), 3.84 (s, 3H, OCH3), 3.88 (ddd, J = 11.3, 8.2, 3.1 Hz, 1H, H-1a), 4.02 
(m, 1H, H-1b), 4.10 (m, 2H, H-2), 4.69 (t, J = 3.6 Hz, 1H, H-2‴), 6.53–6.55 (m, 2H, H-2′, 
H-4′), 6.62 (ddd, J = 8.2, 2.3, 0.6 Hz, 1H, H-6′), 6.92 (dt, J = 7.7, 1.4 Hz, 1H, H-6″), 7.00 
(ddd, J = 8.1, 4.9, 1.5 Hz, 2H, H-3″, H-5″), 7.13 (dt, J = 7.8, 1.5 Hz, 1H, H-4″), 7.17 (t, J = 
8.1 Hz, 1H, H-5′); 13C NMR (125.77 MHz, CDCl3) δ 19.4 (C-4‴), 25.4 (C-5‴), 30.5 
(C-3‴), 56.0 (OCH3), 62.2 (C-6‴), 65.7 (C-1), 67.4 (C-2), 99.0 (C-2‴), 104.0 (C-2′), 108.7 
(C-6′), 109.6 (C-4′), 112.8 (C-3″), 121.1 (C-6″), 121.3 (C-5″), 124.9 (C-4″), 129.8 (C-5′), 
144.8 (C-1″), 151.5 (C-2″), 159.1 (C-1′), 160.1 (C-3′). HRMS (ESI) calcd. for C20H24O5Na 
[M + Na]+ 367.1521; found 367.1515.
3-(2-Methoxyphenoxy)phenoxyethanol (39)
A solution of compound 34 (611 mg, 1.8 mmol) in methanol (10 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg). The reaction mixture was stirred at room 
temperature overnight and was quenched as described for the preparation of 11. The product 
was purified by column chromatography eluting with hexane-EtOAc (87:13) to give 349 mg 
(76% yield) of pure alcohol 39 as a colorless oil: Rf 0.08 (hexane–EtOAc; 4:1); 1H NMR 
(500.13 MHz, CDCl3) δ 2.00 (t, J = 6.2, 1H, -OH), 3.84 (s, 3H, OCH3), 3.94 (m, 2H, H-1), 
4.04 (t, J = 4.5 Hz, 2H, H-2), 6.52–6.55 (m, 2H, H-2′, H-4′), 6.61 (ddd, J = 8.3, 2.3, 0.7 Hz, 
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1H, H-6′), 6.93 (dt, J = 7.7, 1.4 Hz, 1H, H-6″), 7.00 (td, J = 8.1, 1.4 Hz, 2H, H-3″, H-5″), 
7.15 (dt, J = 7.8, 1.4 Hz, 1H, H-4″), 7.18 (t, J = 8.1 Hz, 1H, H-5′); 13C NMR (125.77 MHz, 
CDCl3) δ 56.0 (OCH3), 61.4 (C-1), 69.2 (C-2), 103.8 (C-2′), 108.5 (C-6′), 109.7 (C-4′), 
112.8 (C-3″), 121.1 (C-6″), 121.4 (C-5″), 125.1 (C-4″), 130.0 (C-5′), 144.6 (C-1″), 151.5 
(C-2″), 159.3 (C-1′), 160.0 (C-3′).
3-(2-Methoxyphenoxy)phenoxyethyl 4-Toluenesulfonate (44)
To a solution of 39 (349 mg, 1.34 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (767 mg, 4.02 mmol) following the method of the preparation described for 12. The 
product was purified by column chromatography (silica gel) eluting with hexane–EtOAc 
(9:1) to give 456 mg (82% yield) of pure 44 as a white solid: Rf 0.13 (hexane–EtOAc, 4:1); 
mp 92 °C; 1H NMR (500.13 MHz, CDCl3) δ 2.44 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 4.09 
(m, 2H, H-1), 4.33 (m, 2H, H-2), 6.38 (t, J = 2.4 Hz, 1H, H-2′), 6.47 (ddd, J = 8.3, 2.4, 0.8 
Hz, 1H, H-4′), 6.52 (ddd, J = 8.2, 2.3, 0.8 Hz, 1H, H-6′), 6.93 (ddd, J = 7.8, 7.4, 1.4 Hz, 1H, 
H-6″), 6.98 (dd, J = 7.9, 1.8 Hz, 1H, H-3″), 7.01 (dd, J = 8.2, 1.4 Hz, 1H, H-5″), 7.14 (t, J = 
8.2 Hz, 1H, H-4″), 7.15 (ddd, J = 8.1, 7.1, 2.0 Hz, 1H, H-5′), 7.32 (d, J = 8.0 Hz, 2H, H-3‴), 
7.80 (d, J = 8.3 Hz, 2H, H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.6 (PhCH3), 56.0 
(OCH3), 65.4 (C-1), 68.0 (C-2), 103.9 (C-2′), 108.3 (C-6′), 110.0 (C-4′), 112.8 (C-3″), 121.1 
(C-6″), 121.4 (C-5″), 125.1 (C-4″), 128.0 (C-2‴), 129.8 (C-3‴), 130.0 (C-5′), 132.8 (C-4‴), 
144.6 (C-1″), 144.9 (C-1‴), 151.5 (C-2″), 159.3 (C-1′), 160.0 (C-3′). HRMS (ESI) calcd. for 
C22H23O6S [M+H]+ 415.1215; found 415.1219.
3-(2-Methoxyphenoxy)phenoxyethyl Thiocyanate (49)
To a solution of 44 (449 mg, 1.08 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (526 mg, 5.4 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane-EtOAc (93:7) to afford 156 mg (48% yield) of 49 as a colorless oil: Rf 
0.22 (hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 3.31 (t, J = 5.9 Hz, 2H, H-1), 
3.84 (s, 3H, OCH3), 4.27 (t, J = 5.9 Hz, 2H, H-2), 6.53 (t, J = 2.3 Hz, 1H, H-2′), 6.56 (ddd, J 
= 8.2, 2.3, 0.8 Hz, 1H, H-4′), 6.61 (ddd, J = 8.2, 2.4, 0.7 Hz, 1H, H-6′), 6.94 (dt, J = 7.7, 1.4 
Hz, 1H, H-6″), 7.00 (m, 2H, H-3″, H-5″), 7.15 (ddd, J = 8.1, 7.4, 1.7 Hz, 1H, H-4″), 7.19 (t, 
J = 8.2 Hz, 1H, H-5′); 13C NMR (125.77 MHz, CDCl3) δ 33.3 (C-1), 56.0 (OCH3), 65.8 
(C-2), 103.9 (C-2′), 108.5 (C-6′), 110.2 (C-4′), 111.7 (SCN), 112.9 (C-3″), 121.1 (C-6″), 
121.5 (C-5″), 125.2 (C-4″), 130.1 (C-5′), 144.4 (C-1″), 151.5 (C-2″), 158.9 (C-1′), 159.4 
(C-3′). HRMS (ESI) calcd. for C16H15O3NS [M+Na]+ 324.0670; found 324.0660.
3-(3-Methoxyphenoxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (35)
To a mixture of compound 30 (800 mg, 2.3 mmol), 3-methoxyphenol (570 mg, 4.6 mmol), 
copper (I) iodide (43.8 mg, 0.23 mmol), 2-picolinic acid, (56.6 mg, 0.46 mmol), and 
potassium phosphate tribasic (978 mg, 4.6 mmol) was added dimethyl sulfoxide (3.0 mL) 
and the reaction mixture was stirred at 90 °C for 5 days according to the general procedure. 
The product was purified by column chromatography (silica gel) employing hexane–EtOAc 
(49:1) as eluent to afford 505 mg (64% yield) of pure 35 as a colorless oil: Rf 0.46 (hexane–
EtOAc; 4:1); 1H NMR (500.13 MHz, CDCl3) δ 1.53–1.68 (m, 4H, H-4‴, H-5‴), 1.73–1.79 
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(m, 1H, H-3‴a), 1.82–1.89 (m, 1H, H-3‴b), 3.55 (m, 1H, H-6‴a), 3.81 (s, 3H, OCH3), 3.82 
(ddd, J = 11.0, 6.5, 4.2 Hz, 1H, H-6‴b), 3.91 (ddd, J = 11.3, 8.2, 3.1 Hz, 1H, H-1a), 4.06 (m, 
1H, H-1b), 4.14 (m, 2H, H-2), 4.72 (t, J = 3.6 Hz, 1H, H-2‴), 6.60–6.64 (m, 4H, aromatic 
protons), 6.68 (ddd, J = 8.3, 2.3, 0.8 Hz, 1H, H-6′), 6.71 (ddd, J = 8.3, 2.2, 0.9 Hz, 1H, 
H-6″), 7.24 (t, J = 8.5 Hz, 1H, H-5′), 7.25 (t, J = 8.1 Hz, 1H, H-5″); 13C NMR (125.77 MHz, 
CDCl3) δ 19.3 (C-4‴), 25.4 (C-5‴), 30.5 (C-3‴), 55.3 (OCH3), 62.2 (C-6‴), 65.7 (C-1), 67.5 
(C-2), 99.0 (C-2‴), 105.0 (C-2′), 105.8 (C-2″), 109.0 (C-6′), 109.7 (C-4′), 111.1 (C-4″), 
111.3 (C-6″), 130.0 (C-5′), 130.1 (C-5″), 158.1 (C-1″), 158.2 (C-3″), 160.2 (C-1′), 160.9 
(C-3′). HRMS (ESI) calcd. for C20H24O5Na [M+Na]+ 367.1521; found 367.1516.
3-(3-Methoxyphenoxy)-phenoxyethanol (40)
A solution of compound 5 (852 mg, 2.5 mmol) in methanol (10 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg). The reaction mixture was stirred at room 
temperature overnight and was quenched as described for the preparation of 11. The product 
was purified by column chromatography eluting with hexane–EtOAc (23:2) to give 582 mg 
(90% yield) of pure alcohol 40 as a colorless oil: Rf 0.10 (hexane–EtOAc; 4:1); 1H NMR 
(500.13 MHz, CDCl3) δ 2.01 (br s, 1H, OH), 3.94 (dist t, J = 4.4 Hz, 2H, H-1), 3.78 (s, 3H, 
OCH3), 4.04 (t, J = 4.5 Hz, 2H, H-2), 6.59 (m, 2H, aromatic protons), 6.62 (m, 2H, aromatic 
protons), 6.67 (dd, J = 8.1, 2.2 Hz, 2H, H-6′, H-6″), 7.22 (t, J = 8.1 Hz, 2H, H-5′, H-5″); 13C 
NMR (125.77 MHz, CDCl3) δ 55.4 (OCH3), 61.4 (C-1), 69.2 (C-2), 105.1 (C-2′), 105.5 
(C-2″), 109.1 (C-6′), 109.4 (C-4′), 111.2 (C-4″), 111.5 (C-6″), 130.1 (C-5′), 130.2 (C-5″), 
158.1 (C-1″), 158.3 (C-3″), 159.9 (C-1′), 160.9 (C-3′). HRMS (ESI) calcd. for C15H17O4Na 
[M+Na]+ 283.0946; found 283.0941.
3-(3-Methoxyphenoxy)-phenoxyethyl 4-Toluenesulfonate (45)
To a solution of 36 (582 mg, 2.24 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (1.28 g, 6.71 mmol) following the general method. The product was purified by 
column chromatography (silica gel) eluting with hexane–EtOAc (4:1) to give 209 mg (59% 
yield) of pure 45 as a colorless oil: Rf 0.22 (hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, 
CDCl3) δ 2.43 (s, 3H, CH3), 3.78 (s, 3H, OCH3), 4.10 (m, 2H, H-1), 4.35 (m, 2H, H-2), 6.43 
(t, J = 2.4 Hz, 1H, H-2′), 6.53 (ddd, J = 8.2, 2.4, 0.6 Hz, 1H, aromatic proton), 6.57 (m, 2H, 
aromatic proton), 6.61 (ddd, J = 8.2, 2.2, 0.7 Hz, 1H, H-6′), 6.67 (dd, J = 8.1, 2.2 Hz, 1H, 
H-6″), 7.19 (t, J = 8.2 Hz, 1H, H-5′), 7.23 (t, J = 8.1 Hz, 1H, H-5″), 7.32 (d, J = 8.0 Hz, 2H, 
H-3‴), 7.81 (d, J = 8.3 Hz, 2H, H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.6 (PhCH3), 
55.4 (OCH3), 65.5 (C-1), 68.0 (C-2), 105.1 (C-2′), 105.6 (C-2″), 109.1 (C-6′), 109.2 (C-4′), 
111.2 (C-4″), 111.8 (C-6″), 128.0 (C-2‴), 129.8 (C-3‴), 130.15 (C-5′), 130.18 (C-5″), 132.8 
(C-4‴), 145.0 (C-1‴), 158.1 (C-1″), 158.2 (C-3″), 159.2 (C-1′), 160.9 (C-3′). HRMS (ESI) 
calcd. for C22H23O6SNa [M+Na]+ 437.1035; found 437.1031.
3-(3-Methoxyphenoxy)-phenoxyethyl Thiocyanate (50)
To a solution of 15 (339 mg, 0.82 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (397 mg, 4.1 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (19:1) to afford 112 mg (45% yield) of 50 as a colorless oil: Rf 
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0.31 (hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 3.32 (t, J = 5.8 Hz, 2H, H-1), 
3.79 (s, 3H, OCH3), 4.28 (t, J = 5.8 Hz, 2H, H-2), 6.58–6.62 (m, 3H, aromatic protons), 
6.65–6.69 (m, 3H, aromatic protons), 7.24 (dt, J = 8.2, 3.5 Hz, 2H, H-5′, H-5″); 13C NMR 
(125.77 MHz, CDCl3) δ 33.2 (C-1), 55.4 (OCH3), 65.8 (C-2), 105.2 (C-2′), 105.6 (C-2″), 
109.2 (C-6′), 109.4 (C-4′), 111.3 (C-4″), 111.7 (SCN), 112.1 (C-6″), 130.2 (C-5′), 130.4 
(C-5″), 157.9 (C-1″), 158.4 (C-3″), 159.0 (C-1′), 161.0 (C-3′). HRMS (ESI) calcd. for 
C16H15O3NSNa [M+Na]+ 324.0670; found 324.0661.
3-(2-Pyridyloxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (51)
A mixture of compound 30 (1.051 g, 3.0 mmol), 2-hydroxypyridine (861 mg, 9.0 mmol), 
copper (I) iodide (57.5 mg, 0.30 mmol), 2-picolinic acid, (74.3 mg, 0.60 mmol), and 
potassium phosphate tribasic (1.928 g, 9.0 mmol) in dimethyl sulfoxide (3.0 mL) was stirred 
vigorously at 90 °C for 13 days according to the general procedure The product was purified 
by column chromatography (silica gel) employing hexane–EtOAc (2:3) as eluent to afford 
625 mg (66% yield) of 51 as a colorless oil: Rf 0.49 (EtOAc); 1H NMR (500.13 MHz, 
CDCl3) δ 1.53–1.68 (m, 4H, H-4‴, H-5‴), 1.73–1.79 (m, 1H, H-3‴a), 1.82–1.88 (m, 1H, 
H-3‴b), 3.56 (m, 1H, H-6‴a), 3.85 (ddd, J = 11.3, 6.2, 4.2 Hz, 1H, H-6‴b), 3.92 (ddd, J = 
11.3, 8.3, 3.1 Hz, 1H, H-1a), 4.08 (ddd, J = 11.3, 5.0, 4.2 Hz, 1H, H-1b), 4.20 (m, 2H, H-2), 
4.72 (t, J = 3.6 Hz, 1H, H-2‴), 6.25 (dt, J = 6.7, 1.3 Hz, 1H, H-4″), 6.68 (dq, J = 9.3, 0.7 Hz, 
1H, H-6′), 6.97–7.03 (m, 3H, aromatic protons), 7.34 (ddd, J = 6.9, 2.1, 0.7 Hz, 1H, H-3″), 
7.39–7.43 (m, 2H, aromatic protons); 13C NMR (125.77 MHz, CDCl3) δ 19.3 (C-4‴), 25.4 
(C-5‴), 30.5 (C-3‴), 62.2 (C-6‴), 65.7 (C-1), 67.7 (C-2), 99.0 (C-2‴), 105.8 (C-2′), 113.2 
(C-6′), 115.1 (C-4′), 118.8 (C-6″), 122.0 (C-4″), 130.1 (C-5′), 137.8 (C-5″), 139.8 (C-3″), 
141.9 (C-1″), 159.5 (C-3′,), 162.4 (C-1′). HRMS (ESI) calcd. for C18H22O4NNa [M+Na]+ 
338.1368; found 338.1368.
3-(3-Pyridyloxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (52)
A mixture of compound 30 (900 mg, 2.6 mmol), 3-hydroxypyridine (491 mg, 5.2 mmol), 
copper (I) iodide (49.2 mg, 0.26 mmol), 2-picolinic acid, (63.6 mg, 0.52 mmol), and 
potassium phosphate tribasic (1.100 g, 5.2 mmol) in dimethyl sulfoxide (3.0 mL) was stirred 
at 90 °C for 3 days. The product was purified by column chromatography (silica gel) 
employing hexane–EtOAc (83:17) as eluent to afford 484 mg (59% yield) of pure 52 as a 
colorless oil: Rf 0.09 (hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 1.50–1.65 (m, 
4H, H-4‴, H-5‴), 1.71–1.76 (m, 1H, H-3‴a), 1.79–1.85 (m, 1H, H-3‴b), 3.52 (m, 1H, 
H-6‴a), 3.80 (ddd, J = 11.2, 6.4, 4.1 Hz, 1H, H-6‴b), 3.89 (ddd, J = 11.2, 8.2, 3.1 Hz, 1H, 
H-1a), 4.04 (m, 1H, H-1b), 4.13 (m, 2H, H-2), 4.69 (t, J = 3.7 Hz, 1H, H-2‴), 6.60 (m, 2H, 
aromatic protons), 6.73 (ddd, J = 8.3, 2.2, 0.9 Hz, 1H, H-6′), 7.23–7.32 (m, 3H, H-5″, H-6″), 
8.37 (d, J = 3.7 Hz, 1H, H-4″), 8.41 (d, J = 2.4 Hz, 1H, H-2″); 13C NMR (125.77 MHz, 
CDCl3) δ 19.4 (C-4‴), 25.4 (C-5‴), 30.5 (C-3‴), 62.2 (C-6‴), 65.7 (C-1), 67.6 (C-2), 99.0 
(C-2‴), 105.8 (C-2′), 110.3 (C-6′), 111.2 (C-4′), 124.1 (C-6″), 125.6 (C-5″), 130.4 (C-5′), 
141.6 (C-2″), 144.4 (C-4″), 153.7 (C-1″), 157.5 (C-1′), 160.4 (C-3′).
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3-(4-Pyridyloxy)phenoxyethyl Tetrahydro-2H-pyran-2-yl Ether (53)
A mixture of compound 30 (795 mg, 2.3 mmol), 4-hydroxypyridine (436 mg, 4.6 mmol), 
copper (I) iodide (43.7 mg, 0.23 mmol), 2-picolinic acid, (56.5 mg, 0.46 mmol), and 
potassium phosphate tribasic (976 mg, 4.6 mmol) in dimethyl sulfoxide (3.0 mL) was stirred 
at 90 °C for 2 days. The product was purified by column chromatography (silica gel) 
employing CH2Cl2–MeOH (97:3) as eluent to afford 508 mg (70% yield) of 53 as a 
colorless oil: Rf 0.14 (CH2Cl2–MeOH, 19:1); 1H NMR (500.13 MHz, CDCl3) δ 1.51–1.65 
(m, 4H, H-4‴, H-5‴), 1.72–1.78 (m, 1H, H-3‴a), 1.79–1.86 (m, 1H, H-3‴b), 3.54 (m, 1H, 
H-6‴a), 3.84 (ddd, J = 11.3, 6.4, 4.0 Hz, 1H, H-6‴b), 3.89 (ddd, J = 11.3, 8.3, 3.1 Hz, 1H, 
H-1a), 4.10 (m, 1H, H-1b), 4.21 (m, 2H, H-2), 4.70 (t, J = 3.7 Hz, 1H, H-2‴), 6.49 (d, J = 7.7 
Hz, 2H, H-2″), 6.91 (m, 2H, H-2′, H-4′), 7.00 (ddd, J = 8.3, 2.1, 0.6 Hz, 1H, H-6′), 7.41 (t, J 
= 8.5 Hz, 1H, H-5′), 7.59 (d, J = 7.8 Hz, 2H, H-3″); 13C NMR (125.77 MHz, CDCl3) δ 19.4 
(C-4‴), 25.3 (C-5‴), 30.5 (C-3‴), 62.4 (C-6‴), 65.7 (C-1), 68.0 (C-2), 99.2 (C-2‴), 109.9 
(C-2″), 114.4 (C-2′), 114.9 (C-6′), 119.0 (C-4′), 131.0 (C-5′), 139.0 (C-3″), 144.2 (C-3′), 
159.4 (C-1′), 179.1 (C-1″).
3-(2-Pyridyloxy)phenoxyethanol (54)
A solution of compound 51 (575 mg, 1.82 mmol) in methanol (10 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg). After the usual work up, the residue was purified by 
column chromatography eluting with CH2Cl2–methanol (49:1) to give 281 mg (67% yield) 
of pure alcohol 24 as white solid: Rf 0.12 (EtOAc); mp 95 °C; 1H NMR (500.13 MHz, 
CDCl3) δ 2.04 (br s, 1H, OH), 3.97 (dist t, J = 4.5 Hz, 2H, H-1), 4.12 (dist t, J = 4.6 Hz, 2H, 
H-2), 6.24 (dt, J = 6.7, 1.3 Hz, 1H, H-4″), 6.66 (dq, J = 9.2, 0.7 Hz, 1H, H-6′), 6.96–7.00 (m, 
3H, aromatic protons), 7.33 (ddd, J = 6.9, 2.1, 0.7 Hz, 1H, H-3″), 7.38–7.42 (m, 2H, 
aromatic protons); 13C NMR (125.77 MHz, CDCl3) δ 61.4 (C-1), 69.5 (C-2), 105.8 (C-2′), 
113.2 (C-6′), 115.0 (C-4′), 119.1 (C-6″), 122.0 (C-4″), 130.2 (C-5′), 137.8 (C-5″), 139.9 
(C-3″), 142.0 (C-1″), 159.2 (C-3′,), 162.3 (C-1′).
3-(3-Pyridyloxy)phenoxyethanol (55)
A solution of compound 52 (477 mg, 1.51 mmol) in methanol (3 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg). The reaction mixture was stirred at room 
temperature overnight and was quenched as described for the preparation of 13. The product 
was purified by column chromatography eluting with hexane–EtOAc (1:1) to give 290 mg 
(83% yield) of pure alcohol 55 as a colorless oil: Rf 0.14 (hexane–EtOAc, 1:1); 1H NMR 
(500.13 MHz, CDCl3) δ 2.07 (br s, 1H, OH), 3.96 (m, 2H, H-1), 4.01 (t, J = 4.5 Hz, 2H, 
H-2), 6.60 (t, J = 2.3 Hz, 1H, H-2′), 6.62 (ddd, J = 8.1, 2.3, 0.7 Hz, 1H, H-4′), 6.72 (ddd, J = 
8.3, 2.4, 0.6 Hz, 1H, H-6′), 7.24–7.33 (m, 3H, aromatic protons), 8.38 (dd, J = 4.5, 1.4 Hz, 
1H, H-4″), 8.42 (d, J = 2.7 Hz, 1H, H-2″); 13C NMR (125.77 MHz, CDCl3) δ 61.3 (C-1), 
69.3 (C-2), 105.6 (C-2′), 110.1 (C-6′), 111.4 (C-4′), 124.1 (C-6″), 125.8 (C-5″), 130.5 
(C-5′), 141.6 (C-2″), 144.6 (C-4″), 153.6 (C-1″), 157.6 (C-1′), 160.1 (C-3′).
3-(4-Pyridyloxy)phenoxyethanol (56)
A solution of 53 (617 mg, 1.96 mmol) in methanol (3 mL) was treated with pyridinium 4-
toluenesulfonate (30 mg). The reaction mixture was stirred at room temperature overnight 
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and was quenched as described for the preparation of 13. The product was purified by 
column chromatography eluting with CH2Cl2–MeOH (97:3) to give 156 mg (34% yield) of 
alcohol 56 as white solid: Rf 0.45 (EtOAc–MeOH, 3:2); mp 117 °C; 1H NMR (500.13 MHz, 
CDCl3) δ 2.02 (t, J = 6.2 Hz, 1H, -OH), 4.02 (m, 2H, H-1), 4.15 (t, J = 4.5 Hz, 2H, H-2), 
6.49 (d, J = 7.8 Hz, 2H, H-2″), 6.90 (t, J = 2.3 Hz, 1H, H-2′), 6.95 (ddd, J = 7.9, 2.2, 0.7 Hz, 
1H, H-4′), 6.99 (ddd, J = 8.4, 2.4, 0.7 Hz, 1H, H-6′), 7.43 (t, J = 8.2 Hz, 1H, H-5′), 7.59 (d, J 
= 7.8 Hz, 2H, H-3″); 13C NMR (125.77 MHz, CDCl3) δ 61.3 (C-1), 69.7 (C-2), 109.7 
(C-2″), 114.2 (C-2′), 115.2 (C-6′), 119.0 (C-4′), 131.2 (C-5′), 138.9 (C-3″).
3-(2-Pyridyloxy)phenoxyethyl 4-Toluenesulfonate (57)
To a solution of 54 (284 mg, 1.22 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (702 mg, 3.68 mmol) and the mixture was stirred at room temperature for 4 h. After 
the usual treatment, the residue was purified by column chromatography (silica gel) eluting 
with hexane–EtOAc (35:75) to give 289 mg (61% yield) of pure compound 57 as white 
solid: Rf 0.44 (EtOAc); mp 157 °C; 1H NMR (500.13 MHz, CDCl3) δ 2.44 (s, 3H, PhCH3), 
4.17 (m, 2H, H-1), 4.37 (m, 2H, H-2), 6.24 (dt, J = 6.7, 1.3 Hz, 1H, H-4″), 6.65 (dq, J = 9.3, 
0.6 Hz, 1H, H-6′), 6.82 (t, J = 2.2 Hz, 1H, H-2′), 6.86 (ddd, J = 8.4, 2.5, 0.8 Hz, 1H, H-6″), 
6.96 (ddd, J = 6.9, 2.1, 0.7 Hz, 1H, H-5′), 7.30 (ddd, J = 7.9, 2.0, 0.9 Hz, 1H, H-3″), 7.34–
7.41 (m, 2H, aromatic protons), 7.36 (d, J = 8.1 Hz, 2H, H-3‴), 7.82 (d, J = 8.3 Hz, 2H, 
H-2‴); 13C NMR (125.77 MHz, CDCl3) δ 21.6 (PhCH3), 65.7 (C-1), 67.9 (C-2), 105.9 
(C-2′), 113.3 (C-6′), 114.9 (C-4′), 119.4 (C-6″), 122.0 (C-4″), 128.0 (C-2‴), 129.9 (C-3‴), 
130.2 (C-5′), 137.8 (C-5″), 139.9 (C-3″), 142.0 (C-1″), 145.0 (C-1‴), 158.6 (C-3′,), 162.3 
(C-1′).
3-(3-Pyridyl-3-yloxy)phenoxyethyl 4-Toluenesulfonate (58)
To a solution of 55 (402 mg, 1.74 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (994 mg, 5.21 mmol) following the method of the preparation described for 13. The 
product was purified by column chromatography (silica gel) eluting with hexane–EtOAc 
(3:2) to give 305 mg (46% yield) of pure compound 58 as a colorless oil; Rf 0.69 
(EtOAc); 1H NMR (500.13 MHz, CDCl3) δ 2.44 (s, 3H, PhCH3), 4.13 (m, 2H, H-1), 4.36 
(m, 2H, H-2), 6.45 (t, J = 2.3 Hz, 1H, H-2′), 6.60 (m, 2H, aromatic protons), 7.29 (m, 3H, 
aromatic protons), 7.33 (d, J = 8.1 Hz, 2H, H-3‴), 7.81 (d, J = 8.3 Hz, 2H, H-2‴), 8.38 (dd, 
J = 4.1, 1.5 Hz, 1H, H-4″), 8.40 (d, J = 1.9 Hz, 1H, H-2″); 13C NMR (125.77 MHz, CDCl3) 
δ 21.7 (PhCH3), 65.8 (C-1), 67.9 (C-2), 105.7 (C-2′), 109.9 (C-6′), 111.7 (C-4′), 124.1 
(C-6″), 125.7 (C-5″), 128.0 (C-2‴), 129.9 (C-3‴), 130.5 (C-5′), 132.8 (C-4‴), 141.6 (C-2″), 
144.6 (C-4″), 145.0 (C-1‴), 153.5 (C-1″), 157.5 (C-1′), 159.4 (C-3′). HRMS (ESI) calcd. for 
C20H20O5NS [M+H]+ 386.1062; found 386.1055.
3-(4-Pyridyloxy)phenoxyethyl Bromide (59)
To a mixture of alcohol 56 (153 mg, 0.62 mmol) in methylene chloride (10 mL) at 0 °C was 
added triphenyl phosphine (191 mg, 0.73 mmol) and N-bromosuccinimide (129 mg, 0.73 
mmol). The reaction mixture was stirred at room temperature for 2h. The reaction was 
quenched by addition of water (25 mL). Then, the mixture was extracted with CH2Cl2 (3 × 
15 mL). The combined organic layers were washed with brine (3 × 50 mL), dried (Na2SO4), 
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and the solvent was evaporated. The residue was purified by column chromatography (silica 
gel) eluting with CH2Cl2–MeOH (24:1) to give 45.9 mg (24% yield) of pure 59 as white 
solid: Rf 0.34 (EtOAc–MeOH, 3:2); mp 68 °C; 1H NMR (500.13 MHz, CDCl3) δ 3.67 (t, J = 
6.1 Hz, 2H, H-1), 4.35 (t, J = 6.1 Hz, 2H, H-2), 6.50 (d, J = 7.8 Hz, 2H, H-2″), 6.90 (t, J = 
2.3 Hz, 1H, H-2′), 6.97 (m, 2H, H-4′, H-6′), 7.44 (t, J = 8.2 Hz, 1H, H-5′), 7.59 (d, J = 7.8 
Hz, 2H, H-3″).
3-(2-Pyridyloxy)phenoxyethyl Thiocyanate (60)
To a solution of 57 (288 mg, 0.75 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (363 mg, 3.7 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (45:65) to afford 141 mg (69% yield) of 60 as white solid: Rf 
0.26 (EtOAc); mp 142 °C; 1H NMR (500.13 MHz, CDCl3) δ 3.35 (t, J = 5.8 Hz, 2H, H-1), 
4.35 (t, J = 5.8 Hz, 2H, H-2), 6.24 (dt, J = 6.7, 1.3 Hz, 1H, H-4″), 6.66 (dq, J = 9.2, 0.6 Hz, 
1H, H-6′), 6.98–7.02 (m, 3H, aromatic protons), 7.33 (ddd, J = 6.9, 2.1, 0.7 Hz, 1H, H-3″), 
7.39–7.44 (m, 2H, aromatic protons); 13C NMR (125.77 MHz, CDCl3) δ 33.1 (C-1), 66.0 
(C-2), 106.0 (C-2′), 111.6 (SCN), 113.3 (C-6′), 115.0 (C-4′), 119.8 (C-6″), 122.0 (C-4″), 
130.4 (C-5′), 137.8 (C-5″), 139.9 (C-3″), 142.1 (C-1″), 158.3 (C-3′,), 162.3 (C-1′). HRMS 
(ESI) calcd. for C14H12O2N2SNa [M+Na]+ 295.0517; found 295.0516.
3-(3-Pyridyn-3-yloxy)phenoxyethyl Thiocyanate (61)
To a solution of 58 (245 mg, 0.64 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (309 mg, 3.2 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (65:35) to afford 73.5 mg (64% yield) of 61 as a colorless oil: 
Rf 0.26 (hexane–EtOAc, 1:1); 1H NMR (500.13 MHz, CDCl3) δ 3.33 (t, J = 5.9 Hz, 2H, 
H-1), 4.33 (t, J = 5.8 Hz, 2H, H-2), 6.61 (t, J = 2.3 Hz, 1H, H-2′), 6.65 (ddd, J = 8.2, 2.3, 0.7 
Hz, 1H, H-4′), 6.72 (ddd, J = 8.3, 2.3, 0.6 Hz, 1H, H-6′), 7.27–7.34 (m, 3H, aromatic 
protons), 8.38 (dd, J = 4.6, 1.4 Hz, 1H, H-4″), 8.42 (d, J = 2.7 Hz, 1H, H-2″); 13C NMR 
(125.77 MHz, CDCl3) δ 33.2 (C-1), 65.9 (C-2), 105.8 (C-2′), 110.0 (C-6′), 111.6 (SCN), 
112.0 (C-4′), 124.1 (C-6″), 125.8 (C-5″), 130.7 (C-5′), 141.7 (C-2″), 144.7 (C-4″), 153.4 
(C-1″), 157.7 (C-1′), 159.2 (C-3′). HRMS (ESI) calcd. for C14H13O2N2S [M+H]+ 273.0698; 
found 273.0702.
3-(4-Pyridyloxy)phenoxyethyl Thiocyanate (62)
To a solution of 57 (45.9 mg, 0.16 mmol) in N,N-dimethylformamide (3.0 mL) was added 
potassium thiocyanate (75.8 mg, 0.78 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with CH2Cl2–MeOH (24:1) to afford 37.0 mg (87% yield) of 62 as white solid: Rf 
0.67 (EtOAc–MeOH, 3:2); mp 52 °C; 1H NMR (500.13 MHz, CDCl3) δ 3.37 (t, J = 5.7 Hz, 
2H, H-1), 4.39 (t, J = 5.7 Hz, 2H, H-2), 6.49 (d, J = 7.8 Hz, 2H, H-2″), 6.93 (t, J = 2.3 Hz, 
1H, H-2′), 7.00 (m, 2H, H-4′, H-6′), 7.46 (t, J = 8.2 Hz, 1H, H-5′), 7.60 (d, J = 7.8 Hz, 2H, 
H-3″); 13C NMR (125.77 MHz, CDCl3) δ 33.0 (C-1), 66.3 (C-2), 109.9 (C-2″), 111.4 
(SCN), 113.9 (C-2′), 115.9 (C-6′), 119.0 (C-4′), 131.3 (C-5′), 138.9 (C-3″), 144.3 (C-3′), 
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159.0 (C-1′), 179.0 (C-1″). HRMS (ESI) calcd. for C14H13O2N2S [M+H]+ 273.0698; found 
273.0704.
4-Phenoxyphenoxyethyl Azide (64)
To a solution of 63 (252 mg, 0.66 mmol) in N,N-dimethylformamide (3 mL) was added 
sodium azide (213 mg, 3.28 mmol). The reaction mixture was heated at 100 °C for 3 h. The 
mixture was allowed to cool to room temperature and water (20 mL) was added. The 
aqueous phase was extracted with methylene chloride (2 × 30 mL) and the combined 
organic layers were washed with brine (5 × 30 mL) and water (2 × 30 mL). The solvent was 
dried (Na2SO4) and evaporated. The residue was purified by column chromatography (silica 
gel) eluting with hexane to give 59.5 mg (35% yield) of pure 64 as a colorless oil: Rf 0.44 
(hexane–EtOAc, 4:1); 1H NMR (500.13 MHz, CDCl3) δ 3.60 (t, J = 5.0 Hz, 2H, H-1), 4.14 
(t, J = 5.0 Hz, 2H, H-2), 6.91 (d, J = 9.1 Hz, 2H, H-2′), 6.95 (m, 2H, aromatic protons), 6.99 
(d, J = 9.2 Hz, 2H, H-3′), 7.05 (tt, J = 7.4, 1.1 Hz, 1H, H-4″), 7.30 (m, 2H, aromatic 
protons); 13C NMR (125.77 MHz, CDCl3) δ 50.2 (C-1), 67.5 (C-2), 115.7 (C-2″), 117.7 
(C-2′), 120.8 (C-3′), 122.6 (C-4″), 129.6 (C-3″), 150.8 (C-4′), 154.4 (C-1′), 158.3 (C-1″). 
HRMS (ESI) calcd. for C14H13O2N3Na [M+Na]+ 278.0905; found 278.0892.
2,4-Dibromophenoxyethyl Tetrahydro-2H-pyran-2-yl ether (65)
A solution of 2,4-dibromophenol (1.5 g, 5.95 mmol) in dimethyl sulfoxide (5 mL) was 
treated with potassium hydroxide (668 mg, 11.9 mmol) and bromoethyl tetrahydropyranyl 
ether (1.24 g, 5.95 mmol) according to the general method. The residue was purified by 
column chromatography (silica gel) eluting with hexane–EtOAc (19:1) to afford 293 mg 
(46% yield) of pure 65 as a colorless oil: Rf 0.43 (hexane–EtOAc, 4:1); 1H NMR (500.13 
MHz, CDCl3) δ 1.51–1.63 (m, 4H, H-4‴, H-5‴), 1.71–1.77 (m, 1H, H-3‴a), 1.80–1.84 (m, 
1H, H-3‴b), 3.53 (m, 1H, H-6‴a), 3.86 (ddd, J = 11.0, 5.9, 5.1 Hz, 1H, H-6‴b), 3.92 (ddd, J 
= 11.3, 8.5, 2.9 Hz, 1H, H-1a), 4.07 (m, 1H, H-1b), 4.19 (m, 2H, H-2), 4.77 (t, J = 3.6 Hz, 
1H, H-2‴), 6.82 (d, J = 8.8 Hz, 1H, H-6′), 7.35 (dd, J = 8.7, 2.4 Hz, 1H, H-5′), 7.66 (d, J = 
2.4 Hz, 1H, H-2′); 13C NMR (125.77 MHz, CDCl3) δ 19.2 (C-4″), 25.4 (C-5″), 30.5 (C-3″), 
62.1 (C-6″), 65.4 (C-1), 69.1 (C-2), 99.0 (C-2″), 113.1 (C-4′), 113.2 (C-2′), 114.8 (C-6′), 
131.1 (C-5′), 135.5 (C-3′), 154.8 (C-1′). HRMS (ESI) calcd for C13H16O3Br2Na [M+Na]+ 
400.9364; found 400.9370.
2,4-Dibromophenoxyethanol (66)
A solution of compound 65 (1.04 g, 2.74 mmol) in methanol (10 mL) was treated with 
pyridinium 4-toluenesulfonate (30 mg). The reaction mixture was stirred at room 
temperature overnight and quenched as described for the preparation of 6. The product was 
purified by column chromatography eluting with hexane–EtOAc (43:7) to give 568 mg 
(70% yield) of pure alcohol 66 as white solid: Rf 0.14 (hexane–EtOAc; mp 59 °C; 4:1); 1H 
NMR (500.13 MHz, CDCl3) δ 2.15 (t, J = 6.5 Hz, 1H, OH), 3.99 (dt, J = 6.2, 4.6 Hz, 2H, 
H-1), 4.12 (t, J = 4.5 Hz, 2H, H-2), 6.80 (d, J = 8.7 Hz, 1H, H-6′), 7.38 (dd, J = 8.7, 2.4 Hz, 
1H, H-5′), 7.68 (d, J = 2.4 Hz, 1H, H-2′); 13C NMR (125.77 MHz, CDCl3) δ 61.2 (C-1), 
71.0 (C-2), 113.4 (C-4′), 113.6 (C-2′), 114.9 (C-6′), 131.3 (C-5′), 135.6 (C-3′), 154.3 (C-1′). 
HRMS (ESI) calcd for C8H8O2Br2Na [M + Na]+ 316.8789; found 316.8773.
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2,4-Dibromophenoxyethyl 4-Toluenesulfonate (67)
To a solution of 66 (568 mg, 1.92 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (1.10 g, 5.76 mmol) following the method of the preparation described for 11. The 
product was purified by column chromatography (silica gel) eluting with hexane–EtOAc 
(9:1) to give 725 mg (84% yield) of pure 67 as a colorless oil; Rf 0.33 (hexane–EtOAc, 
4:1); 1H NMR (500.13 MHz, CDCl3) δ 2.44 (s, 3H, PhCH3), 4.22 (m, 2H, H-1), 4.42 (m, 
2H, H-2), 6.71 (d, J = 8.8 Hz, 1H, H-6′), 7.350 (d, J = 8.7, 2H, H-3″), 7.353 (dd, J = 8.5, 2.4 
Hz, 1H, H-5′), 7.66 (d, J = 2.4 Hz, 1H, H-2′), 7.84 (d, J = 8.3, 2H, H-3″); 13C NMR (125.77 
MHz, CDCl3) δ 21.7 (PhCH3), 66.8 (C-1), 67.6 (C-2), 113.4 (C-4′), 114.0 (C-2′), 114.8 
(C-6′), 128.0 (C-2″), 129.9 (C-3″), 131.2 (C-5′), 132.6 (C-4″), 135.7 (C-3′), 145.0 (C-1″), 
153.8 (C-1′). HRMS (ESI) calcd for C15H14O4SBr2Na [M+Na]+ 470.8877; found 470.8864.
2,4-Dibromophenoxyethyl Thiocyanate (68)
To a solution of 67 (725 mg, 1.61 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (782 mg, 8.05 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (23:2) to afford 405 mg (75% yield) of 68 as white solid: Rf 
0.34 (hexane–EtOAc, 4:1); mp 85 °C; 1H NMR (500.13 MHz, CDCl3) δ 3.39 (t, J = 5.9 Hz, 
2H, H-1), 4.34 (t, J = 5.9 Hz, 2H, H-2), 6.81 (d, J = 8.7 Hz, 1H, H-6′), 7.40 (dd, J = 8.7, 2.4 
Hz, 1H, H-5′), 7.70 (d, J = 2.4 Hz, 1H, H-2′); 13C NMR (125.77 MHz, CDCl3) δ 33.0 (C-1), 
67.3 (C-2), 111.5 (SCN), 113.5 (C-4′), 114.5 (C-2′), 115.1 (C-6′), 131.4 (C-5′), 135.9 (C-3′), 
153.6 (C-1′). HRMS (ESI) calcd for C9H7ONSBr2Na [M+Na]+ 357.8513; found 357.8508
3-Pyridyloxyethyl Tetrahydro-2H-pyran-2-yl Ether (69)
A solution of 3-hydroxypyridine (1 g, 10.5 mmol) in dimethyl sulfoxide (5 mL) was treated 
with potassium hydroxide (1.18 g, 21.0 mmol). The suspension was stirred for 30 min at 
room temperature. Then, bromoethyl tetrahydropyranyl ether (2.20 g, 10.5 mmol) was 
added; the reaction mixture was stirred at room temperature overnight. The mixture was 
partitioned between methylene chloride (30 mL) and water (30 mL). The aqueous phase was 
extracted with methylene chloride (2 × 70 mL). The combined organic layers were washed 
with a saturated solution of sodium chloride (2 × 100 mL) and dried (Na2SO4), and the 
solvent was evaporated. The residue was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (7:3) to afford 736 mg (31% yield) of pure 69 as a yellow oil: Rf 
0.26 (hexane–EtOAc, 1:1); 1H NMR (500.13 MHz, CDCl3) δ 1H NMR (500.13 MHz, 
CDCl3) δ 1.52–1.65 (m, 4H, H-4‴, H-5‴), 1.71–1.77 (m, 1H, H-3‴a), 1.81–1.85 (m, 1H, 
H-3‴b), 3.53 (m, 1H, H-6‴a), 3.83 (ddd, J = 11.4, 6.3, 3.9 Hz, 1H, H-6‴b), 3.89 (ddd, J = 
11.2, 8.1, 3.2 Hz, 1H, H-1a), 4.08 (ddd, J = 11.4, 5.2, 4.0 Hz, 1H, H-1b), 4.12 (m, 2H, H-2), 
4.71 (t, J = 3.6 Hz, 1H, H-2‴), 7.23 (m, 2H, aromatic protons), 8.24 (dd, J = 4.4, 1.5 Hz, 1H, 
H-4′), 8.34 (t, J = 2.7 Hz, 1H, H-2′); 13C NMR (125.77 MHz, CDCl3) δ 19.3 (C-4″), 25.3 
(C-5″), 30.4 (C-3″), 62.2 (C-6″), 65.7 (C-1), 67.7 (C-2), 99.1 (C-2″), 121.2 (C-6′), 123.9 
(C-5′), 138.0 (C-2′), 142.5 (C-4′), 154.9 (C-1′). HRMS (ESI) calcd. for C12H18O3N [M+H]+ 
224.1287; found 224.1291.
Chao et al. Page 27
ChemMedChem. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
3-Pyridyloxyethanol (70)
A solution of compound 69 (725 mg, 3.25 mmol) in methanol (3 mL) was treated with 4-
toluenesulfonic acid (30 mg). The reaction mixture was stirred at room temperature 
overnight and was quenched as usual. The product was purified by column chromatography 
eluting with hexane–EtOAc (3:7) to give 304 mg (67% yield) of pure alcohol 70 as a yellow 
oil; Rf 0.19 (EtOAc); 1H NMR (500.13 MHz, CDCl3) δ 2.34 (br s, 1H, OH), 4.00 (dist t, J = 
4.8 Hz, 2H, H-1), 4.14 (dist t, J = 4.1 Hz, 2H, H-2), 7.23 (m, 2H, aromatic protons), 8.24 (t, 
J = 3.0 Hz, 1H, H-4′), 8.34 (t, J = 1.8 Hz, 1H, H-2′); 13C NMR (125.77 MHz, CDCl3) δ 61.3 
(C-1), 69.6 (C-2), 121.2 (C-6′), 123.9 (C-5′), 138.0 (C-2′), 142.5 (C-4′), 154.9 (C-1′). 
HRMS (ESI) calcd. for C7H10O2N [M+H]+ 140.0712; found 140.0710.
3-Pyridyloxyethyl 4-Toluenesulfonate (71)
To a solution of 70 (303 mg, 2.18 mmol) in pyridine (3 mL) was added p-toluenesulfonyl 
chloride (1.25 g, 6.54 mmol) following the method of the preparation described for 13. The 
product was purified by column chromatography (silica gel) eluting with hexane–EtOAc 
(13:7) to give 441 mg (69% yield) of pure 71 as a colorless oil; Rf 0.48 (EtOAc); 1H NMR 
(500.13 MHz, CDCl3) δ 2.45 (s, 3H, PhCH3), 4.21 (m, 2H, H-1), 4.40 (m, 2H, H-2), 7.24 
(m, 2H, aromatic protons), 7.35 (d, J = 8.0, 2H, H-3″), 7.82 (d, J = 8.4, 2H, H-3″), 8.22 (d, J 
= 3.0 Hz, 1H, H-2′), 8.25 (dd, J = 4.7, 1.3 Hz, 1H, H-4′). HRMS (ESI) calcd. for 
C14H16O4NS [M+H]+ 294.0800; found 294.0798.
3-Pyridyloxyethyl Thiocyanate (72)
To a solution of 71 (413 mg, 1.41 mmol) in N,N-dimethylformamide (3 mL) was added 
potassium thiocyanate (683 mg, 7.04 mmol). The reaction mixture was treated according to 
the general procedure. The product was purified by column chromatography (silica gel) 
eluting with hexane–EtOAc (7:3) to afford 107 mg (42% yield) of 72 as a colorless oil: Rf 
0.38 (EtOAc); 1H NMR (500.13 MHz, CDCl3) δ 3.37 (t, J = 5.8 Hz, 2H, H-1), 4.38 (t, J = 
5.8 Hz, 2H, H-2), 7.25 (m, 2H, aromatic protons), 8.30 (dd, J = 4.0, 2.0 Hz, 1H, H-4′), 8.35 
(m, 1H, H-2′); 13C NMR (125.77 MHz, CDCl3) δ 33.1 (C-1), 66.1 (C-2), 111.4 (SCN), 
121.5 (C-6′), 124.0 (C-5′), 137.9 (C-2′), 143.3 (C-4′), 154.1 (C-1′). HRMS (ESI) calcd. for 
C8H8ON2SNa [M+Na]+ 203.0255; found 203.0255.
Drug Screening
T. cruzi amastigote assays
These experiments were done as reported using tdTomato labeled trypomastigotes[31] with 
the modifications described by Recher et al., 2013.[32] ED50 values were determined by non-
linear regression analysis using SigmaPlot.
T. gondii tachyzoites assays
Experiments on T. gondii tachyzoites were carried out as described previously[33] using T. 
gondii tachyzoites expressing red fluorescent protein[34] with the modifications described by 
Recher et al., 2013.[32] Plates were read with covered lids, and both excitation (544 nm) and 
emission (590 nm) were read from the bottom.
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Cytotoxicity for Vero cells
The cytotoxicity was tested using the Alamar BlueTM assay as described by Recher et al., 
2013.[32]
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Chemical structure of WC-9 (compound 1) and other closely related analogues.
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Scheme 1. 
Reagents and conditions: a) Br(CH2)2OTHP, KOH, DMSO, rt, 24 h, 96%; b) H2, Pd/C, 
EtOAc, rt, 4 h, 73%; c) 1-iodo-3-(trifluoromethyl)benzene or 1-iodo-4-
(trifluoromethyl)benzene, 5% CuI, 10% picolinic acid, K3PO4, DMSO, 90 °C, 36 h; d) 
PPTS, MeOH, rt, 24 h; e) TsCl, Py, 0 °C, 4h; e) KSCN, DMF, 80 °C, 48 h.
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Scheme 2. 
Reagents and conditions: a) 2-bromonaphtalene, 5% CuI, 10% picolinic acid, K3PO4, 
DMSO, 90 °C, 24 h, 18%; b) PPTS, MeOH, rt, 4 h, 97%; c) ClTs, py, rt, 4 h, 67%; d) 
KSCN, DMF, 100 °C, 3 h, 43%; e) 1-bromonaphtalene, 5% CuI, 10% picolinic acid, K3PO4, 
DMSO, 90 °C, 24 h, 29%; f) PPTS, MeOH, rt, 4 h, 92%;. g) ClTs, py, rt, 4 h, 91%;.h) 
KSCN, DMF, 100 °C, 3 h, 43%.
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Scheme 3. 
Reagents and conditions: a) 2-hydroxypyridine (1.2 equiv.) 5% CuI, 10% picolinic acid, 
K3PO4, DMSO, 80 °C, 24 h, 48%; b) PPTs, MeOH, rt, 16 h, 60%; c) ClTs, py, 0 °C, then, rt, 
90%; d) KSCN, DMF, 100 °C, 61%.
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Scheme 4. 
Reagents and conditions: a) 5% CuI, 10% picolinic acid, K3PO4, DMSO, 80 °C, 24 h; b) 
PPTs, MeOH, rt, 16 h; c) ClTs, py, 0 °C, 6 h; d) KSCN, DMF,100 °C, 6 h.
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Scheme 5. 
Reagents and conditions: a) 5% CuI, 10% picolinic acid, K3PO4, DMSO, 80 °C, 24 h; b) 
PPTs, MeOH, rt, 16 h; c) NBS, PPh3, CH2Cl2, 0° C, 24%; d) ClTs, py, 0 °C, 6 h; e) KSCN, 
DMF, 100 °C, 6 h.
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Scheme 6. 
Reagents and conditions: a) NaN3, DMF, 100 °C, 6 h, 35%.
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Scheme 7. 
Reagents and conditions: a) KOH, BrCH2CH2OTHP, DMSO, rt, 16 h, 46%; b) PPTs, 
MeOH, rt, 16 h, 70%; c) ClTs, py, 0 °C, 6 h, 84%; d) KSCN, DMF, 100 °C, 6 h, 75%.
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Scheme 8. 
Reagents and conditions: a) KOH, BrCH2CH2OTHP, DMSO, rt, 16 h, 31%; b) PPTs, 
MeOH, rt, 16 h, 46%; ClTs, py, 0 °C, 6 h, 69%; d) KSCN, DMF, 100 °C, 6 h, 42%.
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